Premier (PINC) 10-Q5 Nov 242025 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	3 Months Ended
Cover - shares	Sep. 30, 2024	Oct. 31, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-36092
Entity Registrant Name	Premier, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2477140
Entity Address, Address Line One	13034 Ballantyne Corporate Place
Entity Address, City or Town	Charlotte,
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	28277
City Area Code	704
Local Phone Number	357-0022
Title of 12(b) Security	Class A Common Stock, $0.01 Par Value
Trading Symbol	PINC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		96,108,595
Entity Central Index Key	0001577916
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Assets
Cash and cash equivalents	$ 86,956	$ 125,146
Accounts receivable (net of $2,431 and $1,455 allowance for credit losses, respectively)	98,749	100,965
Contract assets (net of $1,174 and $1,248 allowance for credit losses, respectively)	341,016	335,831
Prepaid expenses and other current assets	76,022	73,653
Current assets of discontinued operations	104,893	116,462
Total current assets	707,636	752,057
Property and equipment (net of $760,993 and $742,063 accumulated depreciation, respectively)	203,957	205,711
Intangible assets (net of $303,970 and $294,333 accumulated amortization, respectively)	259,622	269,259
Goodwill	995,852	995,852
Deferred income tax assets	748,048	776,202
Deferred compensation plan assets	47,380	54,422
Investments in unconsolidated affiliates	230,395	228,562
Operating lease right-of-use assets	17,845	20,635
Other assets	102,863	98,749
Total assets	3,313,598	3,401,449
Liabilities and stockholders' equity
Accounts payable	24,655	22,610
Accrued expenses	47,408	58,482
Revenue share obligations	318,910	292,792
Accrued compensation and benefits	45,072	100,395
Deferred revenue	17,901	19,642
Line of credit and current portion of long-term debt	0	1,008
Current portion of liability related to the sale of future revenues	41,331	51,798
Other current liabilities	56,791	52,589
Current liabilities of discontinued operations	20,163	45,724
Total current liabilities	648,548	746,563
Liability related to the sale of future revenues, less current portion	631,266	599,423
Deferred compensation plan obligations	47,380	54,422
Operating lease liabilities, less current portion	8,067	11,170
Other liabilities	24,154	27,640
Total liabilities	1,359,415	1,439,218
Commitments and contingencies (Note 14)
Stockholders' equity:
Treasury stock, at cost; 6,429,375 shares at June 30, 2024	0	(250,129)
Additional paid-in capital	2,188,208	2,105,684
(Accumulated deficit) retained earnings	(234,995)	105,590
Accumulated other comprehensive loss	(8)	(29)
Total stockholders' equity	1,954,183	1,962,231
Total liabilities and stockholders' equity	3,313,598	$ 3,401,449
Treasury stock, shares (in shares)		6,429,375
Related Party
Liabilities and stockholders' equity
Current portion of notes payable to former limited partners	76,317	$ 101,523
Class A Common Stock
Stockholders' equity:
Class A common stock, $0.01 par value, 500,000,000 shares authorized; 97,794,635 shares issued and outstanding at September 30, 2024 and 111,456,454 shares issued and 105,027,079 shares outstanding at June 30, 2024	$ 978	$ 1,115

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Allowance for doubtful accounts	$ 2,431	$ 1,455
Allowance for credit losses	1,174	1,248
Accumulated depreciation	760,993	742,063
Accumulated amortization	$ 303,970	$ 294,333
Treasury stock, shares (in shares)		6,429,375
Class A Common Stock
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	97,794,635	111,456,454
Common stock outstanding (in shares)	97,794,635	105,027,079

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Net revenue:
Net revenue	$ 248,142	$ 269,026
Cost of revenue:
Cost of revenue	67,724	64,132
Gross profit	180,418	204,894
Operating expenses:
Selling, general and administrative	134,880	133,138
Research and development	586	863
Amortization of purchased intangible assets	9,637	12,553
Operating expenses	145,103	146,554
Operating income	35,315	58,340
Equity in net income (loss) of unconsolidated affiliates	1,833	(1,726)
Interest expense, net	(1,756)	(22)
Other income (expense), net	60,259	(1,092)
Other income (expense), net	60,336	(2,840)
Income before income taxes	95,651	55,500
Income tax expense	22,711	13,731
Net income from continuing operations	72,940	41,769
Net (loss) income from discontinued operations, net of tax	(1,604)	641
Net income	71,336	42,410
Net (income) loss from continuing operations attributable to non-controlling interest	(552)	2,351
Net income attributable to stockholders	70,784	44,761
Comprehensive income:
Net income	71,336	42,410
Comprehensive (income) loss attributable to non-controlling interest	(552)	2,351
Foreign currency translation gain (loss)	21	(3)
Comprehensive income attributable to stockholders	$ 70,805	$ 44,758
Weighted average shares outstanding:
Basic (in shares)	100,380	119,344
Diluted (in shares)	100,991	120,133
Earnings per share attributable to stockholders:
Basic earnings per share from continuing operations (in dollars per share)	$ 0.72	$ 0.37
Basic (loss) earnings per share from discontinued operations (in dollars per share)	(0.01)	0.01
Basic earnings per share attributable to stockholders (in dollars per share)	0.71	0.38
Diluted earnings per share from continuing operations (in dollars per share)	0.72	0.37
Diluted loss per share from discontinued operations (in dollars per share)	(0.02)	0
Diluted earnings per share attributable to stockholders (in dollars per share)	$ 0.70	$ 0.37
Services and software licenses
Cost of revenue:
Cost of revenue	$ 67,724	$ 64,132
Net administrative fees
Net revenue:
Net revenue	132,625	149,886
Software licenses, other services and support
Net revenue:
Net revenue	$ 115,517	$ 119,140

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Class A Common Stock	Common Stock Class A Common Stock	Treasury Stock	Additional Paid-In Capital	(Accumulated Deficit) Retained Earnings	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Jun. 30, 2023			119,158,000
Beginning balance at Jun. 30, 2023	$ 2,334,355		$ 1,256	$ (250,129)	$ 2,178,134	$ 405,102	$ (8)
Treasury stock, beginning balance (in shares) at Jun. 30, 2023				6,429,000
Increase (Decrease) in Stockholders' Equity
Issuance of Class A common stock under equity incentive plan (in shares)			514,000
Issuance of Class A common stock under equity incentive plan	5		$ 5		0
Stock-based compensation expense	6,692				6,692
Repurchase of vested restricted units for employee tax-withholding	(5,178)				(5,178)
Net (loss) income	42,410					42,410
Net income (loss) attributable to non-controlling interest	0				(2,351)	2,351
Change in ownership of consolidated entity	27				27
Dividends	(25,603)					(25,603)
Foreign currency translation adjustment	(3)						(3)
Ending balance (in shares) at Sep. 30, 2023			119,672,000
Ending balance at Sep. 30, 2023	2,352,705		$ 1,261	$ (250,129)	2,177,324	424,260	(11)
Treasury stock, ending balance (in shares) at Sep. 30, 2023				6,429,000
Beginning balance (in shares) at Jun. 30, 2024		105,027,079	105,027,000
Beginning balance at Jun. 30, 2024	$ 1,962,231		$ 1,115	$ (250,129)	2,105,684	105,590	(29)
Treasury stock, beginning balance (in shares) at Jun. 30, 2024	6,429,375			6,429,000
Increase (Decrease) in Stockholders' Equity
Issuance of Class A common stock under equity incentive plan (in shares)			491,000
Issuance of Class A common stock under equity incentive plan	$ 5		$ 5		0
Treasury stock (in shares)		7,723,000		(7,723,000)
Treasury stock	(59,207)			$ (139,207)	80,000
Retirement of Class A common stock (in shares)		0		(14,152,000)
Retirement of Class A common stock	0		$ (142)	$ 389,336		(389,194)
Stock-based compensation expense	6,931				6,931
Repurchase of vested restricted units for employee tax-withholding	(4,985)				(4,985)
Net (loss) income	71,336					71,336
Net income (loss) attributable to non-controlling interest	0				552	(552)
Change in ownership of consolidated entity	26				26
Dividends	(21,590)					(21,590)
Distribution of investment in unconsolidated affiliate to non-controlling interests	(585)
Foreign currency translation adjustment	21						21
Ending balance (in shares) at Sep. 30, 2024		97,794,635	97,795,000
Ending balance at Sep. 30, 2024	$ 1,954,183		$ 978	$ 0	$ 2,188,208	$ (234,995)	$ (8)
Treasury stock, ending balance (in shares) at Sep. 30, 2024				0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]
Dividends declared (in dollars per share)	$ 0.21	$ 0.21

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net income	$ 71,336	$ 42,410
Adjustments to reconcile net income to net cash provided by operating activities:
Net (loss) income from discontinued operations, net of tax	1,604	(641)
Depreciation and amortization	29,288	32,881
Equity in net (income) loss of unconsolidated affiliates	(1,833)	1,726
Deferred income taxes	24,954	(143,435)
Stock-based compensation	6,931	6,692
Other, net	1,672	3,458
Changes in operating assets and liabilities, net of the effects of acquisitions:
Accounts receivable	2,216	4,203
Contract assets	(10,566)	(16,838)
Prepaid expenses and other assets	8,730	10,241
Accounts payable	397	(6,023)
Revenue share obligations	26,118	3,544
Accrued expenses, deferred revenue and other liabilities	(80,804)	124,432
Net cash provided by operating activities from continuing operations	80,043	62,650
Net cash (used in) provided by operating activities from discontinued operations	(12,396)	19,226
Net cash provided by operating activities	67,647	81,876
Investing activities
Purchases of property and equipment	(17,718)	(21,270)
Net cash used in investing activities	(17,718)	(21,270)
Financing activities
Payments on notes payable	(26,214)	(25,823)
Payments on credit facility	0	(215,000)
Proceeds from sale of future revenues	42,325	578,983
Payments on liability related to the sale of future revenues	(20,949)	(4,322)
Cash dividends paid	(21,323)	(25,827)
Repurchase of Class A common stock	(56,440)	0
Other, net	(5,539)	(5,146)
Net cash (used in) provided by financing activities	(88,140)	302,865
Effect of exchange rate changes on cash flows	21	(3)
Net (decrease) increase in cash and cash equivalents	(38,190)	363,468
Cash and cash equivalents at beginning of period	125,146	89,793
Cash and cash equivalents at end of period	$ 86,956	$ 453,261

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	3 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	(1) ORGANIZATION AND BASIS OF PRESENTATION Organization Premier, Inc. (“Premier” or the “Company”) is a publicly held, for-profit Delaware corporation located in the United States. The Company is a holding company with no material business operations of its own. The Company’s primary asset is its equity interest in its wholly owned subsidiary Premier Healthcare Solutions, Inc., a Delaware corporation (“PHSI”). The Company conducts substantially all of its business operations through PHSI and its other consolidated subsidiaries. The Company, together with its subsidiaries and affiliates, is a leading technology-driven healthcare improvement company that unites hospitals, health systems, physicians, employers, product suppliers, service providers, and other healthcare providers and organizations to improve and innovate in the clinical, financial and operational areas of their businesses to meet the demands of a rapidly evolving healthcare industry and continues to expand its capabilities to more fully address and coordinate care improvement and standardization in the employer, payer and life sciences markets. Additionally, the Company also provides some of the various products and services noted above to non-healthcare businesses, including through its direct sourcing activities as well as continued access to its group purchasing organization (“GPO”) programs for non-healthcare members whose contracts were sold to OMNIA Partners, LLC (“OMNIA”) (see Note 9 - Liability Related to the Sale of Future Revenues). The Company’s business model and solutions are designed to provide its members and other customers access to scale efficiencies, spread the cost of their development, provide actionable intelligence derived from anonymized data in the Company’s enterprise data warehouse, mitigate the risk of innovation and disseminate best practices to help the Company’s members and other customers succeed in their transformation to higher quality and more cost-effective healthcare. The Company, together with its subsidiaries and affiliates, delivers its integrated platform of solutions through two business segments: Supply Chain Services and Performance Services. See Note 15 - Segments for further information related to the Company’s reportable business segments. The Company has no significant foreign operations or revenues. The Supply Chain Services segment includes one of the largest national healthcare GPO programs in the United States, serving acute and continuum of care sites and providing supply chain co-management and purchased services activities. In fiscal year 2025, Remitra ® , the Company’s digital invoicing and payables automation business which provides financial support services to healthcare suppliers and providers, began to be reported as a component of the Supply Chain Services segment to align with the Company’s strategy and operations. For comparability purposes, fiscal year 2024 financial measures are presented with Remitra as a component of Supply Chain Services. The Performance Services segment consists of two sub-brands: PINC AI TM , the Company’s technology and services platform with offerings that help optimize performance in three main areas – clinical intelligence, margin improvement and value-based care – using advanced analytics to identify improvement opportunities, consulting and managed services for clinical and operational design, and workflow solutions to hardwire sustainable change in the provider, payer and life sciences markets; and Contigo Health ® , the Company’s direct-to-employer business which provides third-party administrator services and management of health-benefit programs that enable healthcare providers that are also payers (e.g., payviders) and employers to contract directly with healthcare providers as well as partner with healthcare providers to provide employers access to a specialized care network through Contigo Health’s centers of excellence program and cost containment and wrap network. Divestiture of Direct Sourcing Business - Discontinued Operations On September 30, 2024, the Company’s wholly owned subsidiary, Premier Supply Chain Improvement, Inc. (“PSCI”), entered into a Contribution and Exchange Agreement (“CEA”) to exchange all outstanding interests in its direct sourcing subsidiary, SVS LLC d/b/a S2S Global (“S2S Global”), to Prestige Ameritech, Ltd. (“Prestige”) for 9,375,000 limited partnership units, or a 20% minority interest, in Prestige. The transaction closed on October 1, 2024. The Company met the criteria for classifying certain assets and liabilities of the direct sourcing business as a discontinued operation as of September 30, 2024. Accordingly, unless otherwise indicated, information in the notes to the condensed consolidated financial statements has been retrospectively adjusted to reflect continuing operations for all periods presented. See Note 3 - Discontinued Operations and Exit Activities for further information. Principles of Consolidation The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC and in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and include the assets, liabilities, revenues and expenses of all majority-owned subsidiaries over which the Company exercised control and when applicable, entities for which the Company had a controlling financial interest or was the primary beneficiary. All intercompany transactions from continuing operations have been eliminated upon consolidation. Accordingly, certain information and disclosures normally included in annual financial statements have been condensed or omitted. The accompanying condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of results of operations and financial condition for the interim periods shown, consisting of normal recurring adjustments, unless otherwise disclosed. Certain amounts in prior periods have been reclassified to conform to the current period presentation. The Company believes that the disclosures are adequate to make the information presented not misleading and should be read in conjunction with the audited consolidated financial statements and related footnotes contained in the 2024 Annual Report. Supplementary Cash Flows Information The following table presents supplementary cash flows information for the three months ended September 30, 2024 and 2023 (in thousands): Three Months Ended September 30, 2024 2023 Supplemental schedule of non-cash investing and financing activities: Non-cash additions to property and equipment $ 191 $ — Accrued dividend equivalents 450 472 Increase in treasury stock related to a payable as a result of applying trade date accounting when recording the repurchase of Class A common stock 1,602 — Accrued excise taxes related to repurchase of Class A common stock 1,165 — Use of Estimates in the Preparation of Financial Statements The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates are evaluated on an ongoing basis, including, but not limited to, estimates for net administrative fees revenue, software licenses, other services and support revenue, contract assets, deferred revenue, contract costs, allowances for credit losses, reserves for net realizable value of inventory, obsolete inventory, useful lives of property and equipment, stock-based compensation, deferred tax balances including valuation allowances on deferred tax assets, uncertain tax positions, values of investments not publicly traded, projected future cash flows used in the evaluation of asset impairments, values of call rights, values of earn-out liabilities and the allocation of purchase prices. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	(2) SIGNIFICANT ACCOUNTING POLICIES There have been no material changes to the Company’s significant accounting policies as described in the 2024 Annual Report.

DISCONTINUED OPERATIONS AND EXI

DISCONTINUED OPERATIONS AND EXIT ACTIVITIES	3 Months Ended
DISCONTINUED OPERATIONS AND EXIT ACTIVITIES	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS AND EXIT ACTIVITIES	(3) DISCONTINUED OPERATIONS AND EXIT ACTIVITIES In connection with the sale of certain assets and wind down and exit from the direct sourcing business (see Note 1 - Organization and Basis of Presentation), the Company met the criteria for classifying certain assets and liabilities of S2S Global as a discontinued operation as of September 30, 2024. Prior to its classification as a discontinued operation, S2S Global was included as part of the Supply Chain Services segment. The Company’s consolidated subsidiary, PRAM Holdings, LLC (“PRAM”), held an approximate 20% interest in Prestige through PRAM’s ownership of Prestige limited partnership units at September 30, 2024 (see Note 4 – Investments). During the three months ended September 30, 2024 and 2023, the Company recorded net income of $0.3 million and $0.1 million, respectively, within equity in net income (loss) of unconsolidated affiliates. Following the CEA transaction, PRAM’s interest in Prestige will be diluted by an approximate 4% as a result of the additional issuance of limited partnership units to the Company. Premier, through its direct ownership interest in Prestige resulting from the CEA and indirect ownership through PRAM, will hold an aggregate 24% membership interest in Prestige. The ongoing ownership interest represents a continuing involvement which the Company has preliminarily concluded represents an equity method investment. In order to affect the exchange and provide for the relationship between Premier and Prestige, the Company entered into various agreements, including, among others, the CEA and a transition services agreement. As part of the agreements, the Company has agreed to provide certain transitional services as detailed within respective transition services agreements for a period of time not to exceed one year after the sale. Income related to these transitional services will be immaterial. As part of the CEA, Prestige will remit the first $4.0 million of sales associated with a certain international manufacturing facility back to Premier. Any incremental revenue will be retained by Prestige. During the three months ended September 30, 2024 and 2023, the Company recorded revenue of $0.6 million and $0.9 million, respectively, within net administrative fees generated through administrative fees resulting from GPO members’ purchases on S2S Global’s supplier contracts. The Company expects this relationship to continue subsequent to Premier’s disposal of S2S Global. The following table summarizes the major classes of assets and liabilities classified as discontinued operations at September 30, 2024 and June 30, 2024 (in thousands): September 30, 2024 June 30, 2024 Assets Accounts receivable $ 18,345 $ 25,730 Inventory 72,496 79,799 Prepaid expenses and other current assets 6,876 6,893 Deferred income tax assets 3,200 — Other assets 3,976 4,040 Current assets of discontinued operations $ 104,893 $ 116,462 Liabilities Accounts payable $ 14,712 $ 37,750 Accrued expenses 4,573 7,003 Accrued compensation and benefits 878 971 Current liabilities of discontinued operations $ 20,163 $ 45,724 The following table summarizes the major components of net (loss) income from discontinued operations for the three months ended September 30, 2024 and 2023 (in thousands): Three Months Ended September 30, 2024 2023 Net revenue $ 50,485 $ 49,726 Cost of revenue 46,055 44,038 Gross profit 4,430 5,688 Operating expenses: Selling, general and administrative expense 6,761 4,922 Amortization of purchased intangible assets — 135 Operating expenses 6,761 5,057 Operating (loss) income from discontinued operations (2,331) 631 Other (expense) income (54) 217 Net (loss) income from discontinued operations before income taxes (2,385) 848 Income tax (benefit) expense (781) 207 Net (loss) income from discontinued operations, net of tax, attributable to stockholders $ (1,604) $ 641

INVESTMENTS

INVESTMENTS	3 Months Ended
INVESTMENTS	Sep. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENTS	(4) INVESTMENTS Investments in Unconsolidated Affiliates The Company’s investments in unconsolidated affiliates consisted of the following (in thousands): Equity in Net Income (Loss) Carrying Value Three Months Ended September 30, September 30, 2024 June 30, 2024 2024 2023 FFF $ 136,080 $ 136,080 $ — $ — Exela 33,458 32,259 1,198 (1,419) Qventus 16,000 16,000 — — Prestige 15,157 14,850 308 119 Other investments 29,700 29,373 327 (426) Total investments $ 230,395 $ 228,562 $ 1,833 $ (1,726) The Company’s wholly owned subsidiary, Premier Supply Chain Improvement, Inc. (“PSCI”), held a 49% interest in FFF Enterprises, Inc. (“FFF”) through its ownership of stock of FFF at September 30, 2024 and June 30, 2024. On March 3, 2023, the Company and the majority shareholder of FFF amended the FFF shareholders’ agreement and as of the date of the amendment, the Company accounts for its investment in FFF at cost less impairments, if any, plus or minus any observable changes in fair value (refer to the Annual Report on Form 10-K for the fiscal year ended June 30, 2023 for additional information and details regarding the March 2023 amendment). The Company accounts for its investment in FFF as part of the Supply Chain Services segment. The Company’s consolidated subsidiary, ExPre Holdings, LLC (“ExPre”), held an approximate 6% interest in Exela Holdings, Inc. (“Exela”) through ExPre’s ownership of Exela Class A common stock at September 30, 2024 and June 30, 2024. At September 30, 2024 and June 30, 2024, the Company owned approximately 15% of the membership interest of ExPre, with the remainder of the membership interests held by 11 member health systems or their affiliates. The Company accounts for its investment in Exela using the equity method of accounting and includes the investment as part of the Supply Chain Services segment. The Company’s wholly owned subsidiary, PHSI, held an approximate 7% interest in Qventus, Inc. (“Qventus”) through PHSI’s ownership of Qventus Series C preferred stock at September 30, 2024 and June 30, 2024. The Company accounts for its investment in Qventus at cost less impairments, if any, plus or minus any observable changes in fair value. The Company includes Qventus as part of the Performance Services segment. The Company’s consolidated subsidiary, PRAM Holdings, LLC (“PRAM”), held an approximate 20% interest in Prestige Ameritech Ltd. (“Prestige”) through PRAM’s ownership of Prestige limited partnership units at September 30, 2024 and June 30, 2024. At September 30, 2024 and June 30, 2024, the Company owned approximately 26% of the membership interest of PRAM, with the remainder of the membership interests held by 16 member health systems or their affiliates. The Company accounts for its investment in Prestige using the equity method of accounting and includes the investment as part of the Supply Chain Services segment. On September 30, 2024, the Company’s wholly owned subsidiary, PSCI, entered into a contribution and exchange agreement with Prestige. The transaction closed on October 1, 2024, at which time PSCI exchanged all of its holdings in S2S Global for a 20% minority interest in Prestige. As of October 1, 2024, the Company held an approximate 24% interest in Prestige, comprised of the 20% direct ownership interest through its sale of S2S Global (see Note 3 - Discontinued Operations and Exit Activities) as well as its indirect ownership interest through PRAM.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
FAIR VALUE MEASUREMENTS	Sep. 30, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	(5) FAIR VALUE MEASUREMENTS Recurring Fair Value Measurements The following table represents the Company’s financial assets and liabilities, which are measured at fair value on a recurring basis (in thousands): Fair Value of Financial Assets and Liabilities Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs September 30, 2024 Deferred compensation plan assets $ 58,222 $ 58,222 $ — $ — Total assets 58,222 58,222 — — Earn-out liabilities 30,000 — — 30,000 Total liabilities $ 30,000 $ — $ — $ 30,000 June 30, 2024 Deferred compensation plan assets $ 61,198 $ 61,198 $ — $ — Total assets 61,198 61,198 — — Earn-out liabilities 28,549 — — 28,549 Total liabilities $ 28,549 $ — $ — $ 28,549 Deferred compensation plan assets consisted of highly liquid mutual fund investments, which were classified as Level 1. The current portion of deferred compensation plan assets ($10.8 million and $6.8 million at September 30, 2024 and June 30, 2024, respectively) was included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. Financial Instruments Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) Earn-out liabilities Earn-out liabilities have been established in connection with certain acquisitions, including the acquisition of substantially all of the assets and certain liabilities of Acurity, Inc. and Nexera, Inc. (the “Acurity and Nexera asset acquisition”) in February 2020. The earn-out liability related to the Acurity and Nexera asset acquisition was based upon the Company’s achievement of a range of member renewals on terms agreed to by the Company and Greater New York Hospital Association based on prevailing market conditions in December 2023. Earn-out liabilities are classified as Level 3 of the fair value hierarchy. Acurity and Nexera Earn-out (a) The earn-out liability arising from expected earn-out payments related to the Acurity and Nexera asset acquisition was measured on the acquisition date using a probability-weighted expected payment model and was remeasured periodically due to changes in management’s estimates of the number of transferred member renewals and market conditions. In determining the fair value of the contingent liabilities, management reviewed the current results of the acquired business, along with projected results for the remaining earn-out period, to calculate the expected earn-out payment to be made based on the contractual terms set out in the acquisition agreement. The Acurity and Nexera earn-out liability did not utilize a credit spread at September 30, 2024. At June 30, 2024, the Acurity and Nexera earn-out liability utilized a credit spread of 1.0%. At September 30, 2024, the maximum number of transferred member renewals had been achieved. As a result, the earn-out payment was determined to be $30.0 million, which is expected to be paid in the third quarter of fiscal year 2025. The fair value of the Acurity and Nexera earn-out liability at September 30, 2024 and June 30, 2024 was $30.0 million and $28.5 million, respectively. A reconciliation of the Company’s Level 3 earn-out liabilities is as follows (in thousands): Three Months Ended September 30, 2024 2023 Beginning balance $ 28,549 $ 26,603 Purchases (settlements) — — (Gains) losses (a) 1,451 3,258 Ending balance $ 30,000 $ 29,861 _________________________________ (a) Gains on level 3 liability balances will decrease the liability ending balance, and losses on level 3 liability balances will increase the liability ending balance. Non-Recurring Fair Value Measurements As a result of the August 2020 Restructuring, the Company recorded non-interest bearing notes payable to former limited partners during the first quarter of fiscal year 2021. Although these notes are non-interest bearing, they include a Level 2 input associated with an implied fixed annual interest rate of 1.8% (see Note 8 - Debt and Notes Payable). As of September 30, 2024 and June 30, 2024, the notes payable to former limited partners were recorded net of discounts of $0.7 million and $1.2 million, respectively. Financial Instruments for Which Fair Value is Only Disclosed At September 30, 2024, the Company had no non-interest bearing notes payable. At June 30, 2024, the fair values of non-interest bearing notes payable, classified as Level 2, were equal to the carrying value based on an assumed market interest rate of 1.6%. Other Financial Instruments The fair values of cash, accounts receivable, accounts payable, accrued liabilities and the Credit Facility (as defined in Note 8 - Debt and Notes Payable) approximated carrying value due to the short-term nature of these financial instruments.

CONTRACT BALANCES

CONTRACT BALANCES	3 Months Ended
CONTRACT BALANCES	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
CONTRACT BALANCES	(6) CONTRACT BALANCES Deferred Revenue Revenue recognized during the three months ended September 30, 2024 that was included in the opening balance of deferred revenue at June 30, 2024 was $10.0 million, which is a result of satisfying certain performance obligations. Performance Obligations A performance obligation is a contractual obligation to transfer a distinct good or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Contracts may have a single performance obligation as the agreement to transfer individual goods or services is not separately identifiable from other contractual obligations and, therefore, not distinct, while other contracts may have multiple performance obligations, most commonly due to the contract covering multiple phases or deliverable arrangements (licensing fees, software-as-a-service (“SaaS”) subscription fees, maintenance and support fees, and professional fees for consulting services). Refer to the Company’s significant accounting policies in the 2024 Annual Report for discussion of revenue recognition on contracts with customers. Net revenue of $4.7 million was recognized during the three months ended September 30, 2024 from performance obligations that were satisfied or partially satisfied in prior periods. The net revenue recognized was driven by an increase of $4.5 million in net administrative fees revenue related to under-forecasted cash receipts received in the current period and an increase of $0.2 million associated with revised forecasts from underlying contracts that include variable consideration components as well as additional fluctuations due to input method contracts which occur in the normal course of business. Net revenue of $5.3 million was recognized during the three months ended September 30, 2023 from performance obligations that were satisfied or partially satisfied in prior periods. The net revenue recognized was driven by an increase of $3.8 million associated with revised forecasts from underlying contracts that include variable consideration components as well as additional fluctuations due to input method contracts which occur in the normal course of business and an increase of $1.5 million in net administrative fees revenue related to under-forecasted cash receipts received in the current period. Remaining performance obligations represent the portion of the transaction price that has not yet been satisfied or achieved. As of September 30, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $724.8 million. The Company expects to recognize approximately 39% of the remaining performance obligations over the next twelve months, an additional 22% over the following twelve months and an additional 28% over the following 36 months, with the remainder recognized thereafter.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	3 Months Ended
GOODWILL AND INTANGIBLE ASSETS	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	(7) GOODWILL AND INTANGIBLE ASSETS Beginning in fiscal year 2025, Remitra is reported as a component of the Supply Chain Services segment. For comparability purposes, fiscal year 2024 financial measures are presented with Remitra as a component of Supply Chain Services. Fiscal Year 2024 Impairment During the year ended June 30, 2024, the Company recorded pre-tax goodwill and intangible asset impairment charges of $16.5 million and $113.5 million, respectively, related to the Contigo Health reporting unit. At September 30, 2024 and June 30, 2024, the Contigo Health reporting unit’s goodwill and intangible assets were fully impaired. Goodwill At both September 30, 2024 and June 30, 2024, the Company had goodwill balances recorded at Supply Chain Services and Performance Services of $408.3 million and $587.5 million, respectively. At both September 30, 2024 and June 30, 2024, the Company had accumulated impairment losses to goodwill at Performance Services of $70.9 million, all of which related to the Contigo Health reporting unit. Intangible Assets, Net Intangible assets, net consisted of the following (in thousands): September 30, 2024 June 30, 2024 Useful Life Gross Accumulated Amortization Net Gross Accumulated Amortization Net Member relationships 14.7 years $ 386,100 $ (169,449) $ 216,651 $ 386,100 $ (162,910) $ 223,190 Technology 7.1 years 98,517 (74,898) 23,619 98,517 (73,441) 25,076 Customer relationships 9.3 years 41,430 (32,107) 9,323 41,430 (31,612) 9,818 Trade names 6.8 years 18,420 (14,097) 4,323 18,420 (13,574) 4,846 Non-compete agreements 5.2 years 17,315 (12,597) 4,718 17,315 (12,063) 5,252 Other 5.1 years 1,810 (822) 988 1,810 (733) 1,077 Total $ 563,592 $ (303,970) $ 259,622 $ 563,592 $ (294,333) $ 269,259 The net carrying value of intangible assets by segment was as follows (in thousands): September 30, 2024 June 30, 2024 Supply Chain Services $ 249,783 $ 258,480 Performance Services 9,839 10,779 Total intangible assets, net $ 259,622 $ 269,259 The estimated amortization expense for each of the next five fiscal years and thereafter is as follows (in thousands): 2025 (a) $ 28,552 2026 36,945 2027 34,294 2028 30,681 2029 28,687 Thereafter 100,463 Total amortization expense $ 259,622 (a) As of September 30, 2024, estimated amortization expense is for the period from October 1, 2024 to June 30, 2025.

DEBT AND NOTES PAYABLE

DEBT AND NOTES PAYABLE	3 Months Ended
DEBT AND NOTES PAYABLE	Sep. 30, 2024
Debt Disclosure [Abstract]
DEBT AND NOTES PAYABLE	(8) DEBT AND NOTES PAYABLE Long-term debt and notes payable consisted of the following (in thousands): September 30, 2024 June 30, 2024 Notes payable to former limited partners, net of discount $ 76,317 $ 101,523 Other notes payable — 1,008 Total debt and notes payable 76,317 102,531 Less: current portion (76,317) (102,531) Total long-term debt and notes payable $ — $ — Credit Facility PHSI, along with its consolidated subsidiaries, Premier LP and PSCI (“Co-Borrowers”), and certain domestic subsidiaries of the Co-Borrowers, as guarantors, entered into a senior unsecured Amended and Restated Credit Agreement, dated as of December 12, 2022, subsequently amended by a First Amendment to Credit Agreement dated as of September 23, 2024 (the “Credit Facility”). The Credit Facility has a maturity date of December 12, 2027, subject to up to two one-year extensions, and provides for borrowings of up to $1.0 billion with (i) a $50.0 million sub-facility for standby letters of credit and (ii) a $100.0 million sub-facility for swingline loans. The Credit Facility also provides that Co-Borrowers may from time to time (i) incur incremental term loans and (ii) request an increase in the revolving commitments under the Credit Facility, together up to an aggregate of $350.0 million, subject to the approval of the lenders providing such term loans or revolving commitment increase. The Credit Facility contains an unconditional and irrevocable guaranty of all obligations of Co-Borrowers under the Credit Facility by the current and future guarantors. Premier is not a guarantor under the Credit Facility. At both September 30, 2024 and June 30, 2024, the Company had no outstanding borrowings under the Credit Facility with $995.0 million of available borrowing capacity after reductions for outstanding letters of credit. For the three months ended September 30, 2024, the Company had no new borrowings or repayments under the Credit Facility. At both September 30, 2024 and June 30, 2024, the annual commitment fee, based on the actual daily unused amount of commitments under the Credit Facility, was 0.125%. On September 23, 2024, the Credit Facility was amended to revise certain definitions related to the Company’s sale of non-healthcare GPO member contracts to OMNIA (see Note 9 - Liability Related to the Sale of Future Revenues). The Company was in compliance with all covenants at September 30, 2024 and June 30, 2024. Notes Payable Notes Payable to Former Limited Partners At September 30, 2024 and June 30, 2024, the Company had $76.3 million and $101.5 million of notes payable to former limited partners (“LP”), net of discounts on notes payable of $0.7 million and $1.2 million, respectively, recorded to current portion of notes payable to former limited partners in the accompanying Condensed Consolidated Balance Sheets. The notes payable to former LPs were issued in connection with the early termination of the TRA as part of the August 2020 Restructuring. Although the notes payable to former LPs are non-interest bearing, pursuant to GAAP requirements, they were recorded net of imputed interest at a fixed annual rate of 1.8%. Other At June 30, 2024, the Company had $1.0 million in other notes payable, which was included in current portion of long-term debt in the accompanying Condensed Consolidated Balance Sheets. Other notes payable do not bear interest and generally have stated maturities of three

LIABILITY RELATED TO THE SALE O

LIABILITY RELATED TO THE SALE OF FUTURE REVENUES	3 Months Ended
LIABILITY RELATED TO THE SALE OF FUTURE REVENUES	Sep. 30, 2024
Other Liabilities Disclosure [Abstract]
LIABILITY RELATED TO THE SALE OF FUTURE REVENUES	(9) LIABILITY RELATED TO THE SALE OF FUTURE REVENUES Sale of Non-Healthcare GPO Member Contracts On July 25, 2023 (the “Closing Date”), the Company sold the equity interest in its wholly-owned subsidiary, Non-Healthcare Holdings, LLC, pursuant to an equity purchase agreement with OMNIA (“Equity Purchase Agreement”) for a total purchase price of $723.8 million, all of which has been received as of September 30, 2024. Pursuant to the terms of the Equity Purchase Agreement, OMNIA acquired Premier’s non-healthcare GPO member agreements which includes the associated net cash flows generated from administrative fees from purchasing on supplier contracts and in conjunction with the execution of the Equity Purchase Agreement, the Company and OMNIA entered into a 10-year channel partnership agreement (the “Channel Agreement”). Additionally, the Company has the right to retain royalty fees over the term of the Channel Agreement based on the continued growth of the non-healthcare GPO member agreements. As payments for administrative fees are remitted to OMNIA, the balance of Premier’s obligation will effectively be repaid over the term of the Channel Agreement. The Company calculated the effective interest rate based on future expected revenue, which resulted in an effective annual interest rate of 2.5% which will remain consistent throughout the life of the Channel Agreement. Changes to several factors that could materially affect the amount and timing of payments to OMNIA could result in an increase or decrease to expected future revenue and interest expense related to the sale of future revenues. To the extent the amount or timing of future payments varies materially from the original estimate, the Company will make a cumulative adjustment to the carrying amount of the liability, which will be recorded as a non-cash gain or loss in other income in the Condensed Consolidated Statements of Income and Comprehensive Income. For the three months ended September 30, 2024 and 2023, the Company did not record cumulative adjustments to the carrying amount of the liability. At September 30, 2024, the Company had $672.6 million of debt related to the sale of non-healthcare GPO member contracts and associated future revenues, of which $41.3 million was recorded to current portion of the liability related to the sale of future revenues in the accompanying Condensed Consolidated Balance Sheets. For the three months ended September 30, 2024, the Company recorded $15.7 million in revenue that was sold to OMNIA in net administrative fees, net of royalty fees retained, and $4.4 million in interest expense related to the sale of future revenues in interest expense, net in the Condensed Consolidated Statements of Income and Comprehensive Income. A reconciliation of the liability related to the sale of future revenues was as follows (in thousands): Beginning balance as of June 30, 2024 $ 651,221 Proceeds from the sale of future revenues 42,325 Imputed interest expense associated with the sale of future revenues 4,351 Payments against the liability related to the sale of future revenues (25,300) Ending balance as of September 30, 2024 $ 672,597

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
STOCKHOLDERS' EQUITY	Sep. 30, 2024
Equity [Abstract]
STOCKHOLDERS' EQUITY	(10) STOCKHOLDERS' EQUITY As of September 30, 2024, there were 97,794,635 shares of the Company’s Class A common stock (“Common Stock”), par value $0.01 per share, outstanding. Share Repurchase Authorization In February 2024, the Company announced that its Board of Directors approved a new share repurchase authorization for up to $1.0 billion of its Common Stock (the “Share Repurchase Authorization”) and that the Company entered into an accelerated share repurchase agreement (the “ASR Agreement”) with Bank of America, N.A. (“Bank of America”) pursuant to the Share Repurchase Authorization to repurchase an aggregate of $400.0 million of shares of the Company’s Common Stock, excluding fees and expenses. Under the terms of the ASR Agreement, the Company made a payment of $400.0 million to Bank of America and, in February 2024, received initial deliveries of an aggregate of 15.0 million shares of the Company’s Common Stock, or $320.0 million. On July 11, 2024, as final settlement of the share repurchase transaction under the ASR Agreement, the Company received from Bank of America an additional 4.8 million shares of the Company’s Common Stock. In total, the Company repurchased 19.9 million shares of its Common Stock under the ASR Agreement at $20.12 per share, which represents the volume-weighted average share price of the Company’s Common Stock during the term of the ASR Agreement less a discount. The shares delivered were recorded in treasury stock and immediately retired and recorded to retained earnings in the Company’s Condensed Consolidated Balance Sheet. On August 20, 2024, the Company announced that the Company’s Board of Directors approved the execution of another $200.0 million of Common Stock repurchases under the Share Repurchase Authorization. As of September 30, 2024, the Company had repurchased 2.9 million shares of Common Stock at an average price of $20.18 per share for a total purchase price of $58.0 million. There can be no assurances regarding the timing or number of shares of Common Stock purchased under this authorization. The repurchase authorization may be suspended, delayed or discontinued at any time at the discretion of the Company’s Board of Directors. During the three months ended September 30, 2024, the Company paid cash dividends of $0.21 per share on outstanding shares of the Company’s Common Stock to stockholders on September 15, 2024. On October 24, 2024, the Board of Directors declared a quarterly cash dividend of $0.21 per share, payable on December 15, 2024 to stockholders of record on December 1, 2024.

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
EARNINGS PER SHARE	Sep. 30, 2024
Earnings Per Share [Abstract]
EARNINGS PER SHARE	(11) EARNINGS PER SHARE Basic earnings per share is computed by dividing net income attributable to stockholders by the weighted average number of shares of Common Stock outstanding for the period. Except when the effect would be anti-dilutive, the diluted earnings per share calculation, which is calculated using the treasury stock method, includes the impact of all potentially issuable dilutive shares of Common Stock. The following table provides a reconciliation of the numerator and denominator used for basic and diluted earnings per share (in thousands, except per share amounts): Three Months Ended September 30, 2024 2023 Numerator for basic and diluted earnings per share: Net income from continuing operations attributable to stockholders $ 72,388 $ 44,120 Net (loss) income from discontinued operations attributable to stockholders (1,604) 641 Net income attributable to stockholders (a) $ 70,784 $ 44,761 Denominator for earnings per share: Basic weighted average shares outstanding 100,380 119,344 Effect of dilutive securities: (b) Restricted stock units 611 534 Performance share awards — 255 Diluted weighted average shares 100,991 120,133 Earnings per share attributable to stockholders: Basic earnings per share from continuing operations $ 0.72 $ 0.37 Basic (loss) earnings per share from discontinued operations (0.01) 0.01 Basic earnings per share attributable to stockholders $ 0.71 $ 0.38 Diluted earnings per share from continuing operations $ 0.72 $ 0.37 Diluted loss per share from discontinued operations (0.02) — Diluted earnings per share attributable to stockholders $ 0.70 $ 0.37 _________________________________ (a) Net income from continuing operations attributable to stockholders was calculated as follows (in thousands): Three Months Ended September 30, 2024 2023 Net income from continuing operations $ 72,940 $ 41,769 Net (income) loss from continuing operations attributable to non-controlling interest (552) 2,351 Net income from continuing operations attributable to stockholders $ 72,388 $ 44,120 (b) Stock options and restricted stock units excluded from diluted weighted average shares outstanding as their effects were anti-dilutive totaled 1.6 million for the three months ended September 30, 2024. Additionally, performance share awards excluded from diluted weighted average shares outstanding as the awards had not satisfied the applicable performance criteria at the end of the period were 0.3 million for the three months ended September 30, 2024. Stock options and restricted stock units excluded from diluted weighted average shares outstanding as their effects were anti-dilutive totaled 1.3 million for the three months ended September 30, 2023. Additionally, performance share awards excluded from diluted weighted average shares outstanding as the awards had not satisfied the applicable performance criteria at the end of the period were 0.2 million for the three months ended September 30, 2023.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
STOCK-BASED COMPENSATION	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	(12) STOCK-BASED COMPENSATION Stock-based compensation expense is recognized over the requisite service period, which generally equals the stated vesting period. The associated deferred tax benefit was calculated at a tax rate of 25% for the three months ended September 30, 2024 and 2023, which represents the expected effective income tax rate at the time of the compensation expense deduction and differs from the Company’s current effective income tax rate. See Note 13 - Income Taxes for further information related to income taxes. Stock-based compensation expense and the resulting deferred tax benefits were as follows (in thousands): Three Months Ended September 30, 2024 2023 Pre-tax stock-based compensation expense $ 6,931 $ 6,692 Less: deferred tax benefit (a) 1,255 1,544 Total stock-based compensation expense, net of tax $ 5,676 $ 5,148 _________________________________ (a) For the three months ended September 30, 2024 and 2023, the deferred tax benefit was reduced by $0.5 million and $0.2 million, respectively, attributable to stock-based compensation expense that is nondeductible for tax purposes pursuant to Section 162(m) as amended by the Tax Cuts and Jobs Act of 2017. Premier 2013 Equity Incentive Plan The Premier 2013 Equity Incentive Plan, as amended and restated (and including any further amendments thereto, the “2013 Equity Incentive Plan”), provided for grants of up to 14.8 million shares of Common Stock, all of which were eligible to be issued as non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units or performance share awards. On September 24, 2023, the 2013 Equity Incentive Plan expired; no new grants will be issued under the plan. Premier 2023 Equity Incentive Plan The Premier 2023 Equity Incentive Plan (the “2023 Equity Incentive Plan”), which became effective December 1, 2023, provides for grants of up to 6.0 million shares of the Company’s Common Stock, all of which are eligible to be issued as non-qualified stock options, incentive stock options, stock appreciation rights, restricted shares, restricted stock units or performance share awards. As of September 30, 2024, there were approximately 4.1 million shares available for grant under the 2023 Equity Incentive Plan. The following table includes information related to restricted stock, performance share awards and stock options granted under either the 2013 Equity Incentive Plan or the 2023 Equity Incentive Plan for the three months ended September 30, 2024: Restricted Stock Performance Share Awards Stock Options Number of Awards Weighted Average Fair Value at Grant Date Number of Awards Weighted Average Fair Value at Grant Date Number of Options Weighted Average Exercise Price Outstanding at June 30, 2024 2,201,729 $ 28.23 1,578,203 $ 28.14 443,580 $ 33.17 Granted 970,035 20.50 469,847 18.21 — — Vested/exercised (733,180) 31.61 — — — — Forfeited (70,082) 24.93 (63,003) 22.29 (139,761) 32.06 Outstanding at September 30, 2024 2,368,502 $ 24.11 1,985,047 $ 22.40 303,819 $ 33.68 Stock options outstanding and exercisable at September 30, 2024 303,819 $ 33.68 Restricted stock units and restricted stock awards issued prior to June 1, 2023 generally vest in full at the end of a three-year period for employees and a one-year period for directors. Beginning June 1, 2023, restricted stock units and restricted stock awards issued to employees generally vest in equal annual installments over a three-year period. Performance share awards issued and outstanding generally vest at the end of a three-year period subject to whether and to what extent performance targets are met. Stock options generally vest in equal annual installments over a three-year period. Stock options have a term of ten years from the date of grant. Vested stock options will generally expire on the earlier of the scheduled expiration date and twelve months after an employee’s termination with the Company; however, in certain termination circumstances, vested stock options will expire on the earlier of the scheduled expiration date and 90 days after an employee’s termination with the Company. Unrecognized stock-based compensation expense at September 30, 2024 was as follows (in thousands): Unrecognized Stock-Based Compensation Expense Weighted Average Amortization Period Restricted stock $ 43,530 2.2 years Performance share awards 20,126 2.5 years Total unrecognized stock-based compensation expense $ 63,656 2.3 years At September 30, 2024, there was no unrecognized stock-based compensation expense for outstanding stock options. There were no options exercised during the three months ended September 30, 2024, and the stock options outstanding and exercisable at September 30, 2024 had zero aggregate intrinsic value.

INCOME TAXES

INCOME TAXES	3 Months Ended
INCOME TAXES	Sep. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	(13) INCOME TAXES Income tax expense on continuing operations for the three months ended September 30, 2024 and 2023 was $22.7 million and $13.7 million, respectively. This reflects effective tax rates of 24% and 25% for the three months ended September 30, 2024 and 2023, respectively. The change in the effective tax rate is primarily attributable to changes in stock-based compensation expense, state law repricing and statute of limitation release on uncertain tax positions.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	(14) COMMITMENTS AND CONTINGENCIES Operating Leases Operating lease expense for the three months ended September 30, 2024 and 2023 was $2.0 million and $2.4 million, respectively. As of September 30, 2024, the weighted average remaining lease term was 1.9 years and the weighted average discount rate was 6%. Future minimum lease payments under noncancellable operating leases with initial lease terms in excess of one year were as follows (in thousands): September 30, 2024 June 30, 2024 2025 (a) $ 9,525 $ 12,938 2026 9,469 9,469 2027 1,486 1,486 2028 166 166 2029 170 170 Thereafter 309 309 Total future minimum lease payments 21,125 24,538 Less: imputed interest 1,143 1,110 Total operating lease liabilities (b) $ 19,982 $ 23,428 _________________________________ (a) As of September 30, 2024, future minimum lease payments are for the period from October 1, 2024 to June 30, 2025. (b) As of September 30, 2024, the Company had $11.9 million of operating lease liabilities within other current liabilities in the accompanying Condensed Consolidated Balance Sheets. During the three months ended September 30, 2024, the Company had commitments arising from a lease that had not yet commenced related to a lease modification for its corporate headquarters, which is expected to commence in fiscal year 2026 with an initial lease term of approximately eight years. Other Matters The Company is not currently involved in any litigation it believes to be material. The Company is periodically involved in litigation, arising in the ordinary course of business or otherwise, which from time to time may include stockholder derivative or other similar litigation, claims relating to commercial, product liability, tort and personal injury, employment, antitrust, intellectual property, or other regulatory matters. If current or future government regulations, including but not limited to those with respect to antitrust or healthcare laws, are interpreted or enforced in a manner adverse to the Company or its business, the Company may be subject to regulatory inquiries or investigations, enforcement actions, penalties and other material limitations which could have a material adverse effect on the Company’s business, financial condition and results of operations.

SEGMENTS

SEGMENTS	3 Months Ended
SEGMENTS	Sep. 30, 2024
Segment Reporting [Abstract]
SEGMENTS	(15) SEGMENTS The Company delivers its solutions and manages its business through two reportable business segments, the Supply Chain Services segment and the Performance Services segment. The Supply Chain Services segment includes the Company’s GPO, supply chain co-management, purchased services activities and Remitra , the Company’s digital invoicing and payables automation business. The Performance Services segment consists of two sub-brands: PINC AI , the Company’s technology and services platform, and Contigo Health , the Company’s direct-to-employer business. Beginning in fiscal year 2025, Remitra is reported as a component of the Supply Chain Services segment. For comparability purposes, fiscal year 2024 financial measures are presented with Remitra as a component of Supply Chain Services. The following table presents disaggregated revenue by business segment and underlying source (in thousands): Three Months Ended September 30, 2024 2023 Net revenue: Supply Chain Services Net administrative fees $ 132,625 $ 149,886 Software licenses, other services and support 18,763 13,390 Total Supply Chain Services (a) 151,388 163,276 Performance Services Software licenses, other services and support SaaS-based products subscriptions 38,911 45,340 Consulting services 19,689 23,768 Software licenses 20,947 14,738 Other (b) 17,207 21,904 Total Performance Services (a) 96,754 105,750 Net revenue $ 248,142 $ 269,026 _________________________________ (a) Includes intersegment revenue that is eliminated in consolidation. Intersegment revenue is not separately identified in Segments as the amounts are not material. (b) Includes revenue from Contigo Health and certain revenue from PINC AI. Additional segment information related to depreciation and amortization expense, capital expenditures and total assets was as follows (in thousands): Three Months Ended September 30, 2024 2023 Depreciation and amortization expense (a) : Supply Chain Services $ 15,577 $ 14,893 Performance Services 12,223 15,887 Corporate 1,488 2,101 Total depreciation and amortization expense $ 29,288 $ 32,881 Capital expenditures: Supply Chain Services $ 7,335 $ 12,237 Performance Services 10,326 8,118 Corporate 57 915 Total capital expenditures $ 17,718 $ 21,270 September 30, 2024 June 30, 2024 Total assets (b) : Supply Chain Services $ 1,543,392 $ 1,629,042 Performance Services 1,021,640 986,993 Corporate 748,561 785,408 Total assets before eliminations 3,313,593 3,401,443 Eliminations (c) 5 6 Total assets $ 3,313,598 $ 3,401,449 _________________________________ (a) Includes amortization of purchased intangible assets. (b) As of September 30, 2024 and June 30, 2024, Supply Chain Services total assets included $104.9 million and $116.5 million, respectively, in assets of discontinued operations related to S2S Global. (c) Includes eliminations of intersegment transactions which occur during the ordinary course of business. The Company uses Segment Adjusted EBITDA (a financial measure not determined in accordance with generally accepted accounting principles (“Non-GAAP”)) as its primary measure of profit or loss to assess segment performance and to determine the allocation of resources. The Company also uses Segment Adjusted EBITDA to facilitate the comparison of the segment operating performance on a consistent basis from period to period. The Company defines Segment Adjusted EBITDA as the segment’s net revenue less cost of revenue and operating expenses directly attributable to the segment excluding depreciation and amortization, amortization of purchased intangible assets, merger and acquisition-related expense and non-recurring or non-cash items. Operating expenses directly attributable to the segment include expenses associated with sales and marketing, general and administrative and product development activities specific to the operation of each segment. General and administrative corporate expenses that are not specific to a particular segment are not included in the calculation of Segment Adjusted EBITDA. Segment Adjusted EBITDA also excludes any income and expense that has been classified as discontinued operations. The Company has revised the definition for Segment Adjusted EBITDA from the definition reported in the 2024 Annual Report to exclude the operating income from revenues sold to OMNIA in connection with the sale of non-healthcare GPO member contracts, less royalty fees retained. For comparability purposes, prior year Non-GAAP measures are presented based on the current definition. For more information on Segment Adjusted EBITDA and the use of Non-GAAP financial measures, see “Our Use of Non-GAAP Financial Measures” within Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations. A reconciliation of income before income taxes to unaudited Segment Adjusted EBITDA, a Non-GAAP financial measure, is as follows (in thousands): Three Months Ended September 30, 2024 2023 Income before income taxes $ 95,651 $ 55,500 Equity in net (income) loss of unconsolidated affiliates (a) (1,833) 1,726 Interest expense, net 1,756 22 Other (income) expense, net (60,259) 1,092 Operating income 35,315 58,340 Depreciation and amortization 19,651 20,328 Amortization of purchased intangible assets 9,637 12,553 Stock-based compensation (b) 7,140 6,893 Acquisition- and disposition-related expenses 2,884 6,205 Strategic initiative and financial restructuring-related expenses 110 1,746 Operating income from revenues sold to OMNIA (15,710) (11,666) Deferred compensation plan expense (income) (c) 2,692 (1,125) Other reconciling items, net 709 34 Total Non-GAAP Adjusted EBITDA (d) $ 62,428 $ 93,308 Non-GAAP Adjusted EBITDA (d) : Supply Chain Services (e) $ 77,511 $ 101,387 Performance Services (e) 14,949 22,930 Segment Adjusted EBITDA 92,460 124,317 Corporate (30,032) (31,009) Total Non-GAAP Adjusted EBITDA $ 62,428 $ 93,308 _________________________________ (a) Refer to Note 4 - Investments for more information. (b) Includes non-cash employee stock-based compensation expense and stock purchase plan expense of $0.2 million for both the three months ended September 30, 2024 and 2023. (c) Represents changes in deferred compensation plan obligations resulting from realized and unrealized gains and losses and dividend income on deferred compensation plan assets. (d) The definition for Non-GAAP Adjusted EBITDA was revised from the definition reported in the 2024 Annual Report to exclude the operating income from revenues sold to OMNIA in connection with the sale of non-healthcare GPO member contracts, less royalty fees retained. For comparability purposes, prior year Non-GAAP financial measures are presented based on the current definition. (e) Includes intersegment revenue which is eliminated in consolidation.

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	The table below sets forth SEC Rule 10b5-1 trading plans adopted by certain directors and executive officers (as defined in SEC Rule 16a-(f)) during the quarter ended September 30, 2024. Each plan listed in the table was adopted during the quarterly trading window under our Insider Trading Policy. Other than as set forth in the table, during the three months ended September 30, 2024, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K). Trading Arrangement Name and Title Action Date Rule 10b5-1 (a) Non-Rule 10b5-1 (b) Total Shares to be Sold (c) Scheduled Expiration Date (f) Craig S. McKasson, Chief Administrative and Financial Officer Adopt 09/09/2024 X 165,000 06/30/2025 _________________________________ (a) Insider trading plan intended to satisfy the affirmative defense of SEC Rule 10b5-1(c). (b) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K. (c) The numbers in this column represent the maximum number of shares of our Common Stock that may be sold pursuant to each trading plan. The actual number of shares sold pursuant to each trading plan will depend on the satisfaction of certain conditions set forth therein prior to expiration or termination of the plan. (d) Each trading plan terminates on the earlier to occur of: (i) the expiration date listed in the table above; (ii) the first date on which all trades set forth in the plan have been executed; or (iii) such date the plan otherwise terminates according to its terms.
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Directors and Executive Officers' Trading Arrangements [Member] \| Craig S. McKasson [Member]
Trading Arrangements, by Individual
Name	Craig S. McKasson
Title	Chief Administrative and Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	09/09/2024
Expiration Date	06/30/2025
Arrangement Duration	294 days
Aggregate Available	165,000

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC and in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and include the assets, liabilities, revenues and expenses of all majority-owned subsidiaries over which the Company exercised control and when applicable, entities for which the Company had a controlling financial interest or was the primary beneficiary. All intercompany transactions from continuing operations have been eliminated upon consolidation. Accordingly, certain information and disclosures normally included in annual financial statements have been condensed or omitted. The accompanying condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of results of operations and financial condition for the interim periods shown, consisting of normal recurring adjustments, unless otherwise disclosed. Certain amounts in prior periods have been reclassified to conform to the current period presentation. The Company believes that the disclosures are adequate to make the information presented not misleading and should be read in conjunction with the audited consolidated financial statements and related footnotes contained in the 2024 Annual Report.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates are evaluated on an ongoing basis, including, but not limited to, estimates for net administrative fees revenue, software licenses, other services and support revenue, contract assets, deferred revenue, contract costs, allowances for credit losses, reserves for net realizable value of inventory, obsolete inventory, useful lives of property and equipment, stock-based compensation, deferred tax balances including valuation allowances on deferred tax assets, uncertain tax positions, values of investments not publicly traded, projected future cash flows used in the evaluation of asset impairments, values of call rights, values of earn-out liabilities and the allocation of purchase prices. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Goodwill Impairment	During the year ended June 30, 2024, the Company recorded pre-tax goodwill and intangible asset impairment charges of $16.5 million and $113.5 million, respectively, related to the Contigo Health reporting unit. At September 30, 2024 and June 30, 2024, the Contigo Health reporting unit’s goodwill and intangible assets were fully impaired.

ORGANIZATION AND BASIS OF PRE_2

ORGANIZATION AND BASIS OF PRESENTATION (Tables)	3 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION (Tables)	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Supplemental Cash Flow Information	The following table presents supplementary cash flows information for the three months ended September 30, 2024 and 2023 (in thousands): Three Months Ended September 30, 2024 2023 Supplemental schedule of non-cash investing and financing activities: Non-cash additions to property and equipment $ 191 $ — Accrued dividend equivalents 450 472 Increase in treasury stock related to a payable as a result of applying trade date accounting when recording the repurchase of Class A common stock 1,602 — Accrued excise taxes related to repurchase of Class A common stock 1,165 —

DISCONTINUED OPERATIONS AND E_2

DISCONTINUED OPERATIONS AND EXIT ACTIVITIES (Tables)	3 Months Ended
DISCONTINUED OPERATIONS AND EXIT ACTIVITIES (Tables)	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Major Classes of Assets and Liabilities and Major Components of Net Income (Loss) From Discontinued Operations	The following table summarizes the major classes of assets and liabilities classified as discontinued operations at September 30, 2024 and June 30, 2024 (in thousands): September 30, 2024 June 30, 2024 Assets Accounts receivable $ 18,345 $ 25,730 Inventory 72,496 79,799 Prepaid expenses and other current assets 6,876 6,893 Deferred income tax assets 3,200 — Other assets 3,976 4,040 Current assets of discontinued operations $ 104,893 $ 116,462 Liabilities Accounts payable $ 14,712 $ 37,750 Accrued expenses 4,573 7,003 Accrued compensation and benefits 878 971 Current liabilities of discontinued operations $ 20,163 $ 45,724 The following table summarizes the major components of net (loss) income from discontinued operations for the three months ended September 30, 2024 and 2023 (in thousands): Three Months Ended September 30, 2024 2023 Net revenue $ 50,485 $ 49,726 Cost of revenue 46,055 44,038 Gross profit 4,430 5,688 Operating expenses: Selling, general and administrative expense 6,761 4,922 Amortization of purchased intangible assets — 135 Operating expenses 6,761 5,057 Operating (loss) income from discontinued operations (2,331) 631 Other (expense) income (54) 217 Net (loss) income from discontinued operations before income taxes (2,385) 848 Income tax (benefit) expense (781) 207 Net (loss) income from discontinued operations, net of tax, attributable to stockholders $ (1,604) $ 641

INVESTMENTS (Tables)

INVESTMENTS (Tables)	3 Months Ended
INVESTMENTS (Tables)	Sep. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Investments in Unconsolidated Affiliates	The Company’s investments in unconsolidated affiliates consisted of the following (in thousands): Equity in Net Income (Loss) Carrying Value Three Months Ended September 30, September 30, 2024 June 30, 2024 2024 2023 FFF $ 136,080 $ 136,080 $ — $ — Exela 33,458 32,259 1,198 (1,419) Qventus 16,000 16,000 — — Prestige 15,157 14,850 308 119 Other investments 29,700 29,373 327 (426) Total investments $ 230,395 $ 228,562 $ 1,833 $ (1,726)

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities	The following table represents the Company’s financial assets and liabilities, which are measured at fair value on a recurring basis (in thousands): Fair Value of Financial Assets and Liabilities Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs September 30, 2024 Deferred compensation plan assets $ 58,222 $ 58,222 $ — $ — Total assets 58,222 58,222 — — Earn-out liabilities 30,000 — — 30,000 Total liabilities $ 30,000 $ — $ — $ 30,000 June 30, 2024 Deferred compensation plan assets $ 61,198 $ 61,198 $ — $ — Total assets 61,198 61,198 — — Earn-out liabilities 28,549 — — 28,549 Total liabilities $ 28,549 $ — $ — $ 28,549
Schedule of Reconciliation of Earn-out Liabilities	A reconciliation of the Company’s Level 3 earn-out liabilities is as follows (in thousands): Three Months Ended September 30, 2024 2023 Beginning balance $ 28,549 $ 26,603 Purchases (settlements) — — (Gains) losses (a) 1,451 3,258 Ending balance $ 30,000 $ 29,861 _________________________________ (a) Gains on level 3 liability balances will decrease the liability ending balance, and losses on level 3 liability balances will increase the liability ending balance.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	3 Months Ended
GOODWILL AND INTANGIBLE ASSETS (Tables)	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets, net consisted of the following (in thousands): September 30, 2024 June 30, 2024 Useful Life Gross Accumulated Amortization Net Gross Accumulated Amortization Net Member relationships 14.7 years $ 386,100 $ (169,449) $ 216,651 $ 386,100 $ (162,910) $ 223,190 Technology 7.1 years 98,517 (74,898) 23,619 98,517 (73,441) 25,076 Customer relationships 9.3 years 41,430 (32,107) 9,323 41,430 (31,612) 9,818 Trade names 6.8 years 18,420 (14,097) 4,323 18,420 (13,574) 4,846 Non-compete agreements 5.2 years 17,315 (12,597) 4,718 17,315 (12,063) 5,252 Other 5.1 years 1,810 (822) 988 1,810 (733) 1,077 Total $ 563,592 $ (303,970) $ 259,622 $ 563,592 $ (294,333) $ 269,259 The net carrying value of intangible assets by segment was as follows (in thousands): September 30, 2024 June 30, 2024 Supply Chain Services $ 249,783 $ 258,480 Performance Services 9,839 10,779 Total intangible assets, net $ 259,622 $ 269,259
Schedule of Indefinite-Lived Intangible Assets	Intangible assets, net consisted of the following (in thousands): September 30, 2024 June 30, 2024 Useful Life Gross Accumulated Amortization Net Gross Accumulated Amortization Net Member relationships 14.7 years $ 386,100 $ (169,449) $ 216,651 $ 386,100 $ (162,910) $ 223,190 Technology 7.1 years 98,517 (74,898) 23,619 98,517 (73,441) 25,076 Customer relationships 9.3 years 41,430 (32,107) 9,323 41,430 (31,612) 9,818 Trade names 6.8 years 18,420 (14,097) 4,323 18,420 (13,574) 4,846 Non-compete agreements 5.2 years 17,315 (12,597) 4,718 17,315 (12,063) 5,252 Other 5.1 years 1,810 (822) 988 1,810 (733) 1,077 Total $ 563,592 $ (303,970) $ 259,622 $ 563,592 $ (294,333) $ 269,259 The net carrying value of intangible assets by segment was as follows (in thousands): September 30, 2024 June 30, 2024 Supply Chain Services $ 249,783 $ 258,480 Performance Services 9,839 10,779 Total intangible assets, net $ 259,622 $ 269,259
Schedule of Estimated Aggregate Amortization Expense	The estimated amortization expense for each of the next five fiscal years and thereafter is as follows (in thousands): 2025 (a) $ 28,552 2026 36,945 2027 34,294 2028 30,681 2029 28,687 Thereafter 100,463 Total amortization expense $ 259,622 (a) As of September 30, 2024, estimated amortization expense is for the period from October 1, 2024 to June 30, 2025.

DEBT AND NOTES PAYABLE (Tables)

DEBT AND NOTES PAYABLE (Tables)	3 Months Ended
DEBT AND NOTES PAYABLE (Tables)	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Long-Term Debt and Notes Payable	Long-term debt and notes payable consisted of the following (in thousands): September 30, 2024 June 30, 2024 Notes payable to former limited partners, net of discount $ 76,317 $ 101,523 Other notes payable — 1,008 Total debt and notes payable 76,317 102,531 Less: current portion (76,317) (102,531) Total long-term debt and notes payable $ — $ —

LIABILITY RELATED TO THE SALE_2

LIABILITY RELATED TO THE SALE OF FUTURE REVENUES (Tables)	3 Months Ended
LIABILITY RELATED TO THE SALE OF FUTURE REVENUES (Tables)	Sep. 30, 2024
Other Liabilities Disclosure [Abstract]
Schedule of Activity of Liability Related to the Sale of Future Revenues	A reconciliation of the liability related to the sale of future revenues was as follows (in thousands): Beginning balance as of June 30, 2024 $ 651,221 Proceeds from the sale of future revenues 42,325 Imputed interest expense associated with the sale of future revenues 4,351 Payments against the liability related to the sale of future revenues (25,300) Ending balance as of September 30, 2024 $ 672,597

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
EARNINGS PER SHARE (Tables)	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Reconciliation of Common Shares Used for Earnings (Loss) Per Share	The following table provides a reconciliation of the numerator and denominator used for basic and diluted earnings per share (in thousands, except per share amounts): Three Months Ended September 30, 2024 2023 Numerator for basic and diluted earnings per share: Net income from continuing operations attributable to stockholders $ 72,388 $ 44,120 Net (loss) income from discontinued operations attributable to stockholders (1,604) 641 Net income attributable to stockholders (a) $ 70,784 $ 44,761 Denominator for earnings per share: Basic weighted average shares outstanding 100,380 119,344 Effect of dilutive securities: (b) Restricted stock units 611 534 Performance share awards — 255 Diluted weighted average shares 100,991 120,133 Earnings per share attributable to stockholders: Basic earnings per share from continuing operations $ 0.72 $ 0.37 Basic (loss) earnings per share from discontinued operations (0.01) 0.01 Basic earnings per share attributable to stockholders $ 0.71 $ 0.38 Diluted earnings per share from continuing operations $ 0.72 $ 0.37 Diluted loss per share from discontinued operations (0.02) — Diluted earnings per share attributable to stockholders $ 0.70 $ 0.37 _________________________________ (a) Net income from continuing operations attributable to stockholders was calculated as follows (in thousands): Three Months Ended September 30, 2024 2023 Net income from continuing operations $ 72,940 $ 41,769 Net (income) loss from continuing operations attributable to non-controlling interest (552) 2,351 Net income from continuing operations attributable to stockholders $ 72,388 $ 44,120 (b) Stock options and restricted stock units excluded from diluted weighted average shares outstanding as their effects were anti-dilutive totaled 1.6 million for the three months ended September 30, 2024. Additionally, performance share awards excluded from diluted weighted average shares outstanding as the awards had not satisfied the applicable performance criteria at the end of the period were 0.3 million for the three months ended September 30, 2024. Stock options and restricted stock units excluded from diluted weighted average shares outstanding as their effects were anti-dilutive totaled 1.3 million for the three months ended September 30, 2023. Additionally, performance share awards excluded from diluted weighted average shares outstanding as the awards had not satisfied the applicable performance criteria at the end of the period were 0.2 million for the three months ended September 30, 2023.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
STOCK-BASED COMPENSATION (Tables)	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense and Resulting Tax Benefits	Stock-based compensation expense and the resulting deferred tax benefits were as follows (in thousands): Three Months Ended September 30, 2024 2023 Pre-tax stock-based compensation expense $ 6,931 $ 6,692 Less: deferred tax benefit (a) 1,255 1,544 Total stock-based compensation expense, net of tax $ 5,676 $ 5,148 _________________________________ (a) For the three months ended September 30, 2024 and 2023, the deferred tax benefit was reduced by $0.5 million and $0.2 million, respectively, attributable to stock-based compensation expense that is nondeductible for tax purposes pursuant to Section 162(m) as amended by the Tax Cuts and Jobs Act of 2017.
Schedule of Information Related to Restricted Stock	The following table includes information related to restricted stock, performance share awards and stock options granted under either the 2013 Equity Incentive Plan or the 2023 Equity Incentive Plan for the three months ended September 30, 2024: Restricted Stock Performance Share Awards Stock Options Number of Awards Weighted Average Fair Value at Grant Date Number of Awards Weighted Average Fair Value at Grant Date Number of Options Weighted Average Exercise Price Outstanding at June 30, 2024 2,201,729 $ 28.23 1,578,203 $ 28.14 443,580 $ 33.17 Granted 970,035 20.50 469,847 18.21 — — Vested/exercised (733,180) 31.61 — — — — Forfeited (70,082) 24.93 (63,003) 22.29 (139,761) 32.06 Outstanding at September 30, 2024 2,368,502 $ 24.11 1,985,047 $ 22.40 303,819 $ 33.68 Stock options outstanding and exercisable at September 30, 2024 303,819 $ 33.68
Schedule of Information Related to Performance Share Awards	The following table includes information related to restricted stock, performance share awards and stock options granted under either the 2013 Equity Incentive Plan or the 2023 Equity Incentive Plan for the three months ended September 30, 2024: Restricted Stock Performance Share Awards Stock Options Number of Awards Weighted Average Fair Value at Grant Date Number of Awards Weighted Average Fair Value at Grant Date Number of Options Weighted Average Exercise Price Outstanding at June 30, 2024 2,201,729 $ 28.23 1,578,203 $ 28.14 443,580 $ 33.17 Granted 970,035 20.50 469,847 18.21 — — Vested/exercised (733,180) 31.61 — — — — Forfeited (70,082) 24.93 (63,003) 22.29 (139,761) 32.06 Outstanding at September 30, 2024 2,368,502 $ 24.11 1,985,047 $ 22.40 303,819 $ 33.68 Stock options outstanding and exercisable at September 30, 2024 303,819 $ 33.68
Schedule of Information Related to Stock Options	The following table includes information related to restricted stock, performance share awards and stock options granted under either the 2013 Equity Incentive Plan or the 2023 Equity Incentive Plan for the three months ended September 30, 2024: Restricted Stock Performance Share Awards Stock Options Number of Awards Weighted Average Fair Value at Grant Date Number of Awards Weighted Average Fair Value at Grant Date Number of Options Weighted Average Exercise Price Outstanding at June 30, 2024 2,201,729 $ 28.23 1,578,203 $ 28.14 443,580 $ 33.17 Granted 970,035 20.50 469,847 18.21 — — Vested/exercised (733,180) 31.61 — — — — Forfeited (70,082) 24.93 (63,003) 22.29 (139,761) 32.06 Outstanding at September 30, 2024 2,368,502 $ 24.11 1,985,047 $ 22.40 303,819 $ 33.68 Stock options outstanding and exercisable at September 30, 2024 303,819 $ 33.68
Schedule of Unrecognized Stock-Based Compensation Expense	Unrecognized stock-based compensation expense at September 30, 2024 was as follows (in thousands): Unrecognized Stock-Based Compensation Expense Weighted Average Amortization Period Restricted stock $ 43,530 2.2 years Performance share awards 20,126 2.5 years Total unrecognized stock-based compensation expense $ 63,656 2.3 years

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease payments under noncancellable operating leases with initial lease terms in excess of one year were as follows (in thousands): September 30, 2024 June 30, 2024 2025 (a) $ 9,525 $ 12,938 2026 9,469 9,469 2027 1,486 1,486 2028 166 166 2029 170 170 Thereafter 309 309 Total future minimum lease payments 21,125 24,538 Less: imputed interest 1,143 1,110 Total operating lease liabilities (b) $ 19,982 $ 23,428 _________________________________ (a) As of September 30, 2024, future minimum lease payments are for the period from October 1, 2024 to June 30, 2025. (b) As of September 30, 2024, the Company had $11.9 million of operating lease liabilities within other current liabilities in the accompanying Condensed Consolidated Balance Sheets.

SEGMENTS (Tables)

SEGMENTS (Tables)	3 Months Ended
SEGMENTS (Tables)	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Information	The following table presents disaggregated revenue by business segment and underlying source (in thousands): Three Months Ended September 30, 2024 2023 Net revenue: Supply Chain Services Net administrative fees $ 132,625 $ 149,886 Software licenses, other services and support 18,763 13,390 Total Supply Chain Services (a) 151,388 163,276 Performance Services Software licenses, other services and support SaaS-based products subscriptions 38,911 45,340 Consulting services 19,689 23,768 Software licenses 20,947 14,738 Other (b) 17,207 21,904 Total Performance Services (a) 96,754 105,750 Net revenue $ 248,142 $ 269,026 _________________________________ (a) Includes intersegment revenue that is eliminated in consolidation. Intersegment revenue is not separately identified in Segments as the amounts are not material. (b) Includes revenue from Contigo Health and certain revenue from PINC AI. Additional segment information related to depreciation and amortization expense, capital expenditures and total assets was as follows (in thousands): Three Months Ended September 30, 2024 2023 Depreciation and amortization expense (a) : Supply Chain Services $ 15,577 $ 14,893 Performance Services 12,223 15,887 Corporate 1,488 2,101 Total depreciation and amortization expense $ 29,288 $ 32,881 Capital expenditures: Supply Chain Services $ 7,335 $ 12,237 Performance Services 10,326 8,118 Corporate 57 915 Total capital expenditures $ 17,718 $ 21,270 September 30, 2024 June 30, 2024 Total assets (b) : Supply Chain Services $ 1,543,392 $ 1,629,042 Performance Services 1,021,640 986,993 Corporate 748,561 785,408 Total assets before eliminations 3,313,593 3,401,443 Eliminations (c) 5 6 Total assets $ 3,313,598 $ 3,401,449 _________________________________ (a) Includes amortization of purchased intangible assets. (b) As of September 30, 2024 and June 30, 2024, Supply Chain Services total assets included $104.9 million and $116.5 million, respectively, in assets of discontinued operations related to S2S Global. (c) Includes eliminations of intersegment transactions which occur during the ordinary course of business.
Schedule of Reconciliation of (loss) Income Before Income Taxes to Segment Adjusted EBITDA	A reconciliation of income before income taxes to unaudited Segment Adjusted EBITDA, a Non-GAAP financial measure, is as follows (in thousands): Three Months Ended September 30, 2024 2023 Income before income taxes $ 95,651 $ 55,500 Equity in net (income) loss of unconsolidated affiliates (a) (1,833) 1,726 Interest expense, net 1,756 22 Other (income) expense, net (60,259) 1,092 Operating income 35,315 58,340 Depreciation and amortization 19,651 20,328 Amortization of purchased intangible assets 9,637 12,553 Stock-based compensation (b) 7,140 6,893 Acquisition- and disposition-related expenses 2,884 6,205 Strategic initiative and financial restructuring-related expenses 110 1,746 Operating income from revenues sold to OMNIA (15,710) (11,666) Deferred compensation plan expense (income) (c) 2,692 (1,125) Other reconciling items, net 709 34 Total Non-GAAP Adjusted EBITDA (d) $ 62,428 $ 93,308 Non-GAAP Adjusted EBITDA (d) : Supply Chain Services (e) $ 77,511 $ 101,387 Performance Services (e) 14,949 22,930 Segment Adjusted EBITDA 92,460 124,317 Corporate (30,032) (31,009) Total Non-GAAP Adjusted EBITDA $ 62,428 $ 93,308 _________________________________ (a) Refer to Note 4 - Investments for more information. (b) Includes non-cash employee stock-based compensation expense and stock purchase plan expense of $0.2 million for both the three months ended September 30, 2024 and 2023. (c) Represents changes in deferred compensation plan obligations resulting from realized and unrealized gains and losses and dividend income on deferred compensation plan assets. (d) The definition for Non-GAAP Adjusted EBITDA was revised from the definition reported in the 2024 Annual Report to exclude the operating income from revenues sold to OMNIA in connection with the sale of non-healthcare GPO member contracts, less royalty fees retained. For comparability purposes, prior year Non-GAAP financial measures are presented based on the current definition. (e) Includes intersegment revenue which is eliminated in consolidation.

ORGANIZATION AND BASIS OF PRE_3

ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details) shares in Thousands	3 Months Ended
	Sep. 30, 2024 segment brand shares	Oct. 01, 2024
Segment Reporting Information [Line Items]
Number of business segments \| segment	2
Number of sub-brands \| brand	2
Prestige
Segment Reporting Information [Line Items]
Ownership interest (as a percent)	20%	24%
Prestige \| PSCI
Segment Reporting Information [Line Items]
Limited partnership units exchanged in Contribution and Exchange Agreement (in shares) \| shares	9,375

ORGANIZATION AND BASIS OF PRE_4

ORGANIZATION AND BASIS OF PRESENTATION - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Supplemental schedule of non-cash investing and financing activities:
Non-cash additions to property and equipment	$ 191	$ 0
Accrued dividend equivalents	450	472
Increase in treasury stock related to a payable as a result of applying trade date accounting when recording the repurchase of Class A common stock	1,602	0
Accrued excise taxes related to repurchase of Class A common stock	$ 1,165	$ 0

DISCONTINUED OPERATIONS AND E_3

DISCONTINUED OPERATIONS AND EXIT ACTIVITIES - Narrative (Details) $ in Thousands			3 Months Ended
	Oct. 01, 2024	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity in net income			$ 1,833	$ (1,726)
Term of transitional services under the CEA		1 year	1 year
Revenue generated through administrative fees resulting from GPO members			$ 248,142	269,026
Prestige
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership interest (as a percent)	24%	20%	20%
Equity in net income			$ 308	119
Net administrative fees
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue generated through administrative fees resulting from GPO members			132,625	149,886
GPO Members' purchases on S2S Global's supplier contracts \| Net administrative fees
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue generated through administrative fees resulting from GPO members			$ 600	$ 900
Prestige
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue to be remitted to Premier as part of the Contribution and Exchange Agreement		$ 4,000
Subsequent Event \| Prestige
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Dilution of PRAM's interest in Prestige ( percent)	0.04
PRAM Holdings, LLC \| Prestige
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership interest (as a percent)		20%	20%		20%
PRAM Holdings, LLC \| Subsequent Event \| Prestige
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership interest (as a percent)	24%

DISCONTINUED OPERATIONS AND E_4

DISCONTINUED OPERATIONS AND EXIT ACTIVITIES - Major Classes of Assets and Liabilities (Details) - S2S Global Business - Discontinued Operations - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Assets
Accounts receivable	$ 18,345	$ 25,730
Inventory	72,496	79,799
Prepaid expenses and other current assets	6,876	6,893
Deferred income tax assets	3,200	0
Other assets	3,976	4,040
Current assets of discontinued operations	104,893	116,462
Liabilities
Accounts payable	14,712	37,750
Accrued expenses	4,573	7,003
Accrued compensation and benefits	878	971
Current liabilities of discontinued operations	$ 20,163	$ 45,724

DISCONTINUED OPERATIONS AND E_5

DISCONTINUED OPERATIONS AND EXIT ACTIVITIES - Major Components of (Loss) Income from Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating expenses
Net (loss) income from discontinued operations, net of tax, attributable to stockholders	$ (1,604)	$ 641
S2S Global Business \| Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	50,485	49,726
Cost of revenue	46,055	44,038
Gross profit	4,430	5,688
Operating expenses
Selling, general and administrative expense	6,761	4,922
Amortization of purchased intangible assets	0	135
Operating expenses	6,761	5,057
Operating (loss) income from discontinued operations	(2,331)	631
Other (expense) income	(54)	217
Net (loss) income from discontinued operations before income taxes	(2,385)	848
Income tax (benefit) expense	(781)	207
Net (loss) income from discontinued operations, net of tax, attributable to stockholders	$ (1,604)	$ 641

INVESTMENTS - Schedule of Inves

INVESTMENTS - Schedule of Investments in Unconsolidated Affiliates (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Schedule of Equity Method Investments [Line Items]
Carrying Value	$ 230,395		$ 228,562
Equity in Net Income (Loss)	1,833	$ (1,726)
FFF
Schedule of Equity Method Investments [Line Items]
Carrying Value	136,080		136,080
Equity in Net Income (Loss)	0	0
Exela
Schedule of Equity Method Investments [Line Items]
Carrying Value	33,458		32,259
Equity in Net Income (Loss)	1,198	(1,419)
Qventus
Schedule of Equity Method Investments [Line Items]
Carrying Value	16,000		16,000
Equity in Net Income (Loss)	0	0
Prestige
Schedule of Equity Method Investments [Line Items]
Carrying Value	15,157		14,850
Equity in Net Income (Loss)	308	119
Other investments
Schedule of Equity Method Investments [Line Items]
Carrying Value	29,700		$ 29,373
Equity in Net Income (Loss)	$ 327	$ (426)

INVESTMENTS - Narrative (Detail

INVESTMENTS - Narrative (Details) - health_system	Oct. 01, 2024	Sep. 30, 2024	Jun. 30, 2024
FFF
Schedule of Equity Method Investments [Line Items]
Ownership interest (as a percent)		49%	49%
Exela \| ExPre Holdings, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest (as a percent)		6%	6%
ExPre Holdings, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest (as a percent)		15%	15%
Number of member health systems		11	11
Prestige
Schedule of Equity Method Investments [Line Items]
Ownership interest (as a percent)	24%	20%
Prestige \| PRAM Holdings, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest (as a percent)		20%	20%
PRAM Holdings, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest (as a percent)		26%	26%
Number of member health systems		16	16
Qventus
Schedule of Equity Method Investments [Line Items]
Ownership interest (as a percent)		7%	7%

FAIR VALUE MEASUREMENTS - Sched

FAIR VALUE MEASUREMENTS - Schedule of Financial Assets and Liabilities (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation plan assets	$ 58,222	$ 61,198
Total assets	58,222	61,198
Earn-out liabilities	30,000	28,549
Total liabilities	30,000	28,549
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation plan assets	58,222	61,198
Total assets	58,222	61,198
Earn-out liabilities	0	0
Total liabilities	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation plan assets	0	0
Total assets	0	0
Earn-out liabilities	0	0
Total liabilities	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation plan assets	0	0
Total assets	0	0
Earn-out liabilities	30,000	28,549
Total liabilities	$ 30,000	$ 28,549

FAIR VALUE MEASUREMENTS - Narra

FAIR VALUE MEASUREMENTS - Narrative (Details) $ in Thousands	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Aug. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assumed market interest rate (percent)		1.60%
Notes payable to former limited partners, net of discount \| Notes Payable, Other Payables
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Imputed interest (percent)			1.80%
Discount	$ 700	$ 1,200
Acurity, Inc. (“Acurity”) and Nexera, Inc. (“Nexera”)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out payment	30,000
Earn-out liabilities	30,000	$ 28,500
Acurity, Inc. (“Acurity”) and Nexera, Inc. (“Nexera”) \| Credit Spread \| Valuation Technique, Estimated Future Earnings
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out input assumptions (percent)		0.010
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out liabilities	30,000	$ 28,549
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out liabilities	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Imputed interest (percent)			1.80%
Significant Other Observable Inputs (Level 2) \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out liabilities	0	0
Prepaid Expenses and Other Current Assets \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current portion of deferred compensation plan assets	$ 10,800	$ 6,800

FAIR VALUE MEASUREMENTS - Sch_2

FAIR VALUE MEASUREMENTS - Schedule of Reconciliation of Earn-Out Liabilities and FFF Put and Call Rights (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Nonoperating Income (Expense)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Nonoperating Income (Expense)
Earn-Out
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Beginning balance	$ 28,549	$ 26,603
Purchases (settlements)	0	0
(Gains)/losses	1,451	3,258
Ending balance	$ 30,000	$ 29,861

CONTRACT BALANCES - Contract As

CONTRACT BALANCES - Contract Assets, Deferred Revenue and Capitalized Contract Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue recognized	$ 10
Revenue recognized from performance obligations satisfied in previous periods	4.7	$ 5.3
Revenue recognized associated with revised forecasts underlying contracts with variable consideration components	0.2	3.8
Administrative Fees
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue recognized associated with a change in net administration fee revenue	$ 4.5	$ 1.5

CONTRACT BALANCES - Remaining P

CONTRACT BALANCES - Remaining Performance Obligation (Details) $ in Millions	Sep. 30, 2024 USD ($)
Revenue from Contract with Customer [Abstract]
Transaction price allocated to remaining performance obligation	$ 724.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation to be satisfied (percent)	39%
Remaining performance obligation satisfaction period (in months)	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation to be satisfied (percent)	22%
Remaining performance obligation satisfaction period (in months)	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation to be satisfied (percent)	28%
Remaining performance obligation satisfaction period (in months)	36 months

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2023	Sep. 30, 2024	Jun. 30, 2024
Goodwill [Line Items]
Goodwill		$ 995,852	$ 995,852
Contigo Health Reporting Unit
Goodwill [Line Items]
Goodwill impairment	$ 16,500
Impairment of intangible assets	$ 113,500
Performance Services
Goodwill [Line Items]
Goodwill		587,500
Accumulated impairment loss		70,900	$ 70,900
Supply Chain Services
Goodwill [Line Items]
Goodwill		$ 408,300

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Finite-Lived Intangible Assets [Line Items]
Gross	$ 563,592	$ 563,592
Accumulated Amortization	(303,970)	(294,333)
Net	$ 259,622	269,259
Member relationships
Finite-Lived Intangible Assets [Line Items]
Useful Life	14 years 8 months 12 days
Gross	$ 386,100	386,100
Accumulated Amortization	(169,449)	(162,910)
Net	$ 216,651	223,190
Technology
Finite-Lived Intangible Assets [Line Items]
Useful Life	7 years 1 month 6 days
Gross	$ 98,517	98,517
Accumulated Amortization	(74,898)	(73,441)
Net	$ 23,619	25,076
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Useful Life	9 years 3 months 18 days
Gross	$ 41,430	41,430
Accumulated Amortization	(32,107)	(31,612)
Net	$ 9,323	9,818
Trade names
Finite-Lived Intangible Assets [Line Items]
Useful Life	6 years 9 months 18 days
Gross	$ 18,420	18,420
Accumulated Amortization	(14,097)	(13,574)
Net	$ 4,323	4,846
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Useful Life	5 years 2 months 12 days
Gross	$ 17,315	17,315
Accumulated Amortization	(12,597)	(12,063)
Net	$ 4,718	5,252
Other
Finite-Lived Intangible Assets [Line Items]
Useful Life	5 years 1 month 6 days
Gross	$ 1,810	1,810
Accumulated Amortization	(822)	(733)
Net	988	1,077
Performance Services
Finite-Lived Intangible Assets [Line Items]
Net	$ 9,839	$ 10,779

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets by Segment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, net	$ 259,622	$ 269,259
Supply Chain Services
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, net	249,783	258,480
Performance Services
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, net	$ 9,839	$ 10,779

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Aggregate Amortization Expense (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 28,552
2026	36,945
2027	34,294
2028	30,681
2029	28,687
Thereafter	100,463
Net	$ 259,622

DEBT AND NOTES PAYABLE - Schedu

DEBT AND NOTES PAYABLE - Schedule of Long-Term Debt and Notes Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Debt Instrument [Line Items]
Total debt and notes payable	$ 76,317	$ 102,531
Less: current portion	(76,317)	(102,531)
Total long-term debt and notes payable	0	0
Notes Payable \| Notes payable to former limited partners, net of discount
Debt Instrument [Line Items]
Total debt and notes payable	76,317	101,523
Notes Payable \| Other notes payable
Debt Instrument [Line Items]
Total debt and notes payable	$ 0	$ 1,008

DEBT AND NOTES PAYABLE - Credit

DEBT AND NOTES PAYABLE - Credit Facility (Narrative) (Details)				3 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 23, 2024 USD ($) extension	Jun. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Line of Credit Facility [Line Items]
Outstanding borrowings	$ 76,317,000		$ 102,531,000	$ 76,317,000
Payments on credit facility				0	$ 215,000,000
Credit Facility
Line of Credit Facility [Line Items]
Number of available extensions \| extension		2
Duration of each available extension		1 year
Maximum borrowing capacity		$ 1,000,000,000
Additional borrowing capacity		350,000,000
Outstanding borrowings	0		$ 0	0
Available borrowing capacity	$ 995,000,000			995,000,000
Proceeds from credit facility				0
Payments on credit facility				$ 0
Credit facility, unused capacity commitment fee (percent)	0.125%		0.125%
Letters of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity		50,000,000
Swing Line Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity		$ 100,000,000

DEBT AND NOTES PAYABLE - Notes

DEBT AND NOTES PAYABLE - Notes Payable (Narrative) (Details) - Notes Payable - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Aug. 31, 2020
Minimum
Debt Instrument [Line Items]
Notes payable, stated maturity period	3 years
Maximum
Debt Instrument [Line Items]
Notes payable, stated maturity period	5 years
Notes payable to former limited partners, net of discount
Debt Instrument [Line Items]
Notes payable	$ 76.3	$ 101.5
Debt discount	0.7	1.2
Notes payable included in current portion of long-term debt	$ 0.7	1.2
Imputed interest (percent)			1.80%
Other notes payable
Debt Instrument [Line Items]
Notes payable		1
Notes payable included in current portion of long-term debt		$ 1

LIABILITY RELATED TO THE SALE_3

LIABILITY RELATED TO THE SALE OF FUTURE REVENUES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	14 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Jun. 30, 2024	Jul. 25, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current portion of liability related to the sale of future revenues	$ 41,331	$ 41,331	$ 51,798
Non-Healthcare Holdings, LLC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Estimated purchase price (up to)				$ 723,800
Aggregate consideration received		723,800
Partnership agreement term				10 years
Debt related to the sale of non-healthcare GPO member contracts and associated future revenues	672,597	672,597	$ 651,221
Current portion of liability related to the sale of future revenues	41,300	$ 41,300
Revenue recorded net of royalty fee	15,700
Imputed interest expense associated with the sale of future revenues	$ 4,351
Non-Healthcare Holdings, LLC \| Liability Related To The Sale Of Future Revenues
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest rate (percent)				2.50%

LIABILITY RELATED TO THE SALE_4

LIABILITY RELATED TO THE SALE OF FUTURE REVENUES - Schedule of Activity of Liability Related to the Sale of Future Revenues (Details) - Non-Healthcare Holdings, LLC $ in Thousands	3 Months Ended
	Sep. 30, 2024 USD ($)
Liability, Sale Of Future Revenues [Roll Forward]
Beginning balance as of June 30, 2024	$ 651,221
Proceeds from the sale of future revenues	42,325
Imputed interest expense associated with the sale of future revenues	4,351
Payments against the liability related to the sale of future revenues	(25,300)
Ending balance as of September 30, 2024	$ 672,597

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended		5 Months Ended
	Oct. 24, 2024	Jul. 11, 2024	Feb. 09, 2024	Feb. 05, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Jul. 11, 2024	Aug. 20, 2024	Jun. 30, 2024	Feb. 29, 2024
Class of Stock [Line Items]
Aggregate share repurchase authorization											$ 1,000,000
Repurchase of Class A common stock						$ 56,440	$ 0
Dividends declared (in dollars per share)						$ 0.21	$ 0.21
Subsequent Event
Class of Stock [Line Items]
Dividends declared (in dollars per share)	$ 0.21
Class A Common Stock
Class of Stock [Line Items]
Common stock outstanding (in shares)					97,794,635	97,794,635				105,027,079
Common stock, par value (in dollars per share)					$ 0.01	$ 0.01				$ 0.01
Class A Common Stock \| ASR Agreement
Class of Stock [Line Items]
Aggregate share repurchase authorization				$ 400,000					$ 200,000
Repurchase of Class A common stock				$ 400,000
Stock repurchased during period (in shares)		4,800,000	15,000,000		2,900,000			19,900,000
Shares repurchased			$ 320,000		$ 58,000
Price paid for share repurchases under the ASR program (in dollars per share)					$ 20.18			$ 20.12

EARNINGS PER SHARE - Reconcilia

EARNINGS PER SHARE - Reconciliation of the Numerator and Denominator Used for Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Numerator for basic and diluted earnings per share:
Net income from continuing operations attributable to stockholders	$ 72,388	$ 44,120
Net (loss) income from discontinued operations attributable to stockholders	(1,604)	641
Net income attributable to stockholders	$ 70,784	$ 44,761
Denominator for earnings per share:
Basic weighted average shares outstanding (in shares)	100,380	119,344
Effect of dilutive securities:
Diluted weighted average shares (in shares)	100,991	120,133
Earnings per share attributable to stockholders:
Basic earnings per share from continuing operations (in dollars per share)	$ 0.72	$ 0.37
Basic (loss) earnings per share from discontinued operations (in dollars per share)	(0.01)	0.01
Basic earnings per share attributable to stockholders (in dollars per share)	0.71	0.38
Diluted earnings per share from continuing operations (in dollars per share)	0.72	0.37
Diluted loss per share from discontinued operations (in dollars per share)	(0.02)	0
Diluted earnings per share attributable to stockholders (in dollars per share)	$ 0.70	$ 0.37
Net income from continuing operations	$ 72,940	$ 41,769
Net (income) loss from continuing operations attributable to non-controlling interest	(552)	2,351
Net income from continuing operations attributable to stockholders	$ 72,388	$ 44,120
Restricted stock units
Effect of dilutive securities:
Effect of dilutive securities (in shares)	611	534
Performance share awards
Effect of dilutive securities:
Effect of dilutive securities (in shares)	0	255
Earnings per share attributable to stockholders:
Antidilutive securities excluded from computation of earnings per share (in shares)	300	200
Options and Restricted Stock Units
Earnings per share attributable to stockholders:
Antidilutive securities excluded from computation of earnings per share (in shares)	1,600	1,300

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended
	May 31, 2023	Sep. 30, 2024	Sep. 24, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected effective income tax rate (percent)		25%
Number of shares available for grant (in shares)			0
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards authorized for grant (up to) (in shares)		14,800,000
Unrecognized stock-based compensation expense		$ 63,656
Options exercised in the period (in shares)		0
Intrinsic value of options outstanding and exercisable		$ 0
2023 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards authorized for grant (up to) (in shares)		6,000,000
Number of shares available for grant (in shares)		4,100,000
Restricted stock units and Restricted stock awards \| 2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		3 years
Performance share awards \| 2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		3 years
Unrecognized stock-based compensation expense		$ 20,126
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense		$ 0
Stock options \| 2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		3 years
Stock options, expiration period		10 years
Stock options \| 2013 Equity Incentive Plan \| Share-Based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period		12 months
Stock options \| 2013 Equity Incentive Plan \| Share-Based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period		90 days
Employee \| Restricted stock units and Restricted stock awards \| 2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Director \| Restricted stock units and Restricted stock awards \| 2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	1 year

STOCK-BASED COMPENSATION - Sche

STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense and Resulting Tax Benefits (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Pre-tax stock-based compensation expense	$ 6,931	$ 6,692
Less: deferred tax benefit	1,255	1,544
Total stock-based compensation expense, net of tax	5,676	5,148
Reduction (increase) in deferred tax benefit	$ 500	$ 200

STOCK-BASED COMPENSATION - Sc_2

STOCK-BASED COMPENSATION - Schedule of Information Related to Restricted Stock, Performance Share Awards and Stock Options (Details)	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Restricted Stock
Number of Awards
Outstanding, beginning balance (in shares) \| shares	2,201,729
Granted (in shares) \| shares	970,035
Vested/exercised (in shares) \| shares	(733,180)
Forfeited (in shares) \| shares	(70,082)
Outstanding, ending balance (in shares) \| shares	2,368,502
Weighted Average Fair Value at Grant Date
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 28.23
Granted (in dollars per share) \| $ / shares	20.50
Vested/exercised (in dollars per share) \| $ / shares	31.61
Forfeited (in dollars per share) \| $ / shares	24.93
Outstanding, ending balance (in dollars per share) \| $ / shares	$ 24.11
Performance Share Awards
Number of Awards
Outstanding, beginning balance (in shares) \| shares	1,578,203
Granted (in shares) \| shares	469,847
Vested/exercised (in shares) \| shares	0
Forfeited (in shares) \| shares	(63,003)
Outstanding, ending balance (in shares) \| shares	1,985,047
Weighted Average Fair Value at Grant Date
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 28.14
Granted (in dollars per share) \| $ / shares	18.21
Vested/exercised (in dollars per share) \| $ / shares	0
Forfeited (in dollars per share) \| $ / shares	22.29
Outstanding, ending balance (in dollars per share) \| $ / shares	$ 22.40
Stock options
Number of Options
Outstanding, beginning balance (in shares) \| shares	443,580
Granted (in shares) \| shares	0
Vested/exercised (in shares) \| shares	0
Forfeited (in shares) \| shares	(139,761)
Outstanding, ending balance (in shares) \| shares	303,819
Stock options outstanding and exercisable (in shares) \| shares	303,819
Weighted Average Exercise Price
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 33.17
Granted (in dollars per share) \| $ / shares	0
Vested/exercised (in dollars per share) \| $ / shares	0
Forfeited (in dollars per share) \| $ / shares	32.06
Outstanding, ending balance (in dollars per share) \| $ / shares	33.68
Stock options outstanding and exercisable (in dollars per share) \| $ / shares	$ 33.68

STOCK-BASED COMPENSATION - Sc_3

STOCK-BASED COMPENSATION - Schedule of Unrecognized Stock-Based Compensation Expense (Details) - 2013 Equity Incentive Plan $ in Thousands	3 Months Ended
	Sep. 30, 2024 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Stock-Based Compensation Expense	$ 63,656
Weighted Average Amortization Period	2 years 3 months 18 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Stock-Based Compensation Expense	$ 43,530
Weighted Average Amortization Period	2 years 2 months 12 days
Performance share awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Stock-Based Compensation Expense	$ 20,126
Weighted Average Amortization Period	2 years 6 months

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 22,711	$ 13,731
Effective tax rate (percent)	24%	25%

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Operating lease expense	$ 2	$ 2.4
Remaining lease term (in years)	1 year 10 months 24 days
Discount rate (percent)	6%
Lease not yet commenced, initial lease term	8 years

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Rental Payments for Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
Remainder of the current fiscal year	$ 9,525
Year one	9,469	$ 12,938
Year two	1,486	9,469
Year three	166	1,486
Year four	170	166
Year five		170
Thereafter	309
Thereafter		309
Total future minimum lease payments	21,125	24,538
Less: imputed interest	1,143	1,110
Total operating lease liabilities	$ 19,982	$ 23,428
Operating lease, liability, current, statement of financial position [Extensible List]	Other current liabilities	Other current liabilities
Operating lease liability included in other current liabilities	$ 11,900

SEGMENTS - Narrative (Details)

SEGMENTS - Narrative (Details)	3 Months Ended
SEGMENTS - Narrative (Details)	Sep. 30, 2024 segment brand
Segment Reporting Information [Line Items]
Number of reportable business segments \| segment	2
Number of sub-brands \| brand	2

SEGMENTS - Schedule of Segment

SEGMENTS - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Segment Reporting Information [Line Items]
Net revenue	$ 248,142	$ 269,026
Total depreciation and amortization expense	29,288	32,881
Total capital expenditures	17,718	21,270
Total assets	3,313,598		$ 3,401,449
Current assets of discontinued operations	104,893		116,462
Net administrative fees
Segment Reporting Information [Line Items]
Net revenue	132,625	149,886
Software licenses, other services and support
Segment Reporting Information [Line Items]
Net revenue	115,517	119,140
Operating Segments \| Supply Chain Services
Segment Reporting Information [Line Items]
Net revenue	151,388	163,276
Total depreciation and amortization expense	15,577	14,893
Total capital expenditures	7,335	12,237
Total assets	1,543,392		1,629,042
Current assets of discontinued operations	104,900		116,500
Operating Segments \| Performance Services
Segment Reporting Information [Line Items]
Net revenue	96,754	105,750
Total depreciation and amortization expense	12,223	15,887
Total capital expenditures	10,326	8,118
Total assets	1,021,640		986,993
Operating Segments \| Operating Segments and Corporate Non-segment
Segment Reporting Information [Line Items]
Total assets	3,313,593		3,401,443
Operating Segments \| Net administrative fees \| Supply Chain Services
Segment Reporting Information [Line Items]
Net revenue	132,625	149,886
Operating Segments \| Software licenses, other services and support \| Supply Chain Services
Segment Reporting Information [Line Items]
Net revenue	18,763	13,390
Operating Segments \| SaaS-based products subscriptions \| Performance Services
Segment Reporting Information [Line Items]
Net revenue	38,911	45,340
Operating Segments \| Consulting services \| Performance Services
Segment Reporting Information [Line Items]
Net revenue	19,689	23,768
Operating Segments \| Software licenses \| Performance Services
Segment Reporting Information [Line Items]
Net revenue	20,947	14,738
Operating Segments \| Other \| Performance Services
Segment Reporting Information [Line Items]
Net revenue	17,207	21,904
Corporate
Segment Reporting Information [Line Items]
Total depreciation and amortization expense	1,488	2,101
Total capital expenditures	57	$ 915
Total assets	748,561		785,408
Eliminations
Segment Reporting Information [Line Items]
Total assets	$ 5		$ 6

SEGMENTS - Reconciliation of (l

SEGMENTS - Reconciliation of (loss) Income Before Income Taxes to Segment Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Income before income taxes	$ 95,651	$ 55,500
Equity in net (income) loss of unconsolidated affiliates	(1,833)	1,726
Interest expense, net	1,756	22
Other (income) expense, net	(60,259)	1,092
Operating income	35,315	58,340
Depreciation and amortization	19,651	20,328
Amortization of purchased intangible assets	9,637	12,553
Stock-based compensation	7,140	6,893
Acquisition- and disposition-related expenses	2,884	6,205
Strategic initiative and financial restructuring-related expenses	110	1,746
Operating income from revenues sold to OMNIA	(15,710)	(11,666)
Deferred compensation plan expense (income)	2,692	(1,125)
Other reconciling items, net	709	34
Non-GAAP Adjusted EBITDA	62,428	93,308
Employee Stock Purchase Plan (ESPP)
Segment Reporting Information [Line Items]
Stock-based compensation	200	200
Operating Segments
Segment Reporting Information [Line Items]
Non-GAAP Adjusted EBITDA	92,460	124,317
Operating Segments \| Supply Chain Services
Segment Reporting Information [Line Items]
Non-GAAP Adjusted EBITDA	77,511	101,387
Operating Segments \| Performance Services
Segment Reporting Information [Line Items]
Non-GAAP Adjusted EBITDA	14,949	22,930
Corporate
Segment Reporting Information [Line Items]
Non-GAAP Adjusted EBITDA	$ (30,032)	$ (31,009)